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Access to healthcare is a critical public health issue in the United States, especially for 
veterans. Veterans are older on average than the general U.S. population and are thus at 
higher risk for chronic disease. Further, veterans report more delays when seeking healthcare. 
The Veterans Affairs (VA) Healthcare System continuously works to develop policies and 
technologies that aim to improve veteran access to care. Industrial engineering methods can 
be effective in analyzing the impact of such policies, as well as designing or modifying 
systems to better align veteran patients’ needs with providers and resources. This dissertation 
demonstrates how industrial engineering tools can guide policy decisions to improve 
healthcare access by connecting veterans with the most appropriate healthcare resources, 
while highlighting the trade-offs inherent in such decisions. 
This work comprises four stages: (1) using optimization methods to design a 
healthcare network when introducing new provider options for chronic disease screening, (2) 
developing simulation tools to model how access to care is impacted when scheduling policies 
accommodate patient preferences, and (3) simulating triage strategies for non-emergency care 
during COVID-19, and (4) evaluating how treatment decisions impact patient access when 
guided by risk-based prediction models compared to current practice.  
In the first stage, we consider veteran access to chronic eye disease screening. 
Ophthalmologists in the VA have developed a platform in which ophthalmic technicians 
screen patients for major chronic eye diseases during primary care visits. We use mixed-
 xv 
integer programming-based facility location models to understand how the VA can determine 
which clinics should offer eye screenings, which provider type(s) should staff those clinics, 
and how to distribute patients among clinics. The results of this work show how the VA can 
achieve various objectives including minimizing the cost or maximizing the number of 
patients receiving care. 
In the second stage, we simulate patients seeking care for gastroesophageal reflux 
disease with primary care and gastrointestinal providers. This simulation incorporates policies 
about how to schedule patients for visits in various modalities, including face-to-face and 
telehealth, and also considers uncertainty in key factors like patient arrivals and 
demographics. Results of these models can help us understand how scheduling based on these 
preferences impacts access, including time to first appointment and number of patients seen. 
Such metrics can guide healthcare administrators as new technologies are introduced that 
offer options for how patients interact with their providers. 
In the third stage, we simulate patients seeking non-emergency outpatient care under 
reduced appointment capacity due to the COVID-19 pandemic. We demonstrate this using 
endoscopy visits as a central example. We use our simulation model to understand how 
various strategies for adjusting patient triage and/or clinic operations can mitigate patient 
backlog and reduce patient waiting times. 
In the fourth stage, we integrate multiple industrial engineering methods to examine 
how access is impacted among chronic liver disease patients when predictive modeling is 
introduced into treatment planning. We developed a simulation model to help clinical 
decision-makers better understand how using a predictive model may change the care pathway 
for a specific patient and also impact system decisions, such as required staffing levels and 
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clinical data acquired at specific patient visits. The model also helps clinicians understand the 
value of specific clinical data (lab values, vitals, etc.) by demonstrating how better or worse 
inputs to the predictive models have larger system impacts to patient access.  
 
 1 
Chapter 1. Introduction 
 1.1. Motivation 
Access to appropriate, affordable, and timely healthcare services is a major issue in the 
United States. Kullgren et al. (2012) showed that 29% of Americans reported having an unmet 
health need or delayed seeking care due to some barrier and 21% of those reporting access 
issues encounter nonfinancial barriers. (1) Access to healthcare was conceptually defined in 
1981 by Penchansky and Thomas. (2) Prior to the Penchansky and Thomas definition, Aday 
and Anderson conceived of a relatively simple framework that solely considered socio-
organizational and geographic dimensions of access. (3) Carrillo et al. (2011) created the 
Health Care Access Barriers (HCAB) model, which considers financial, structural, and 
cognitive barriers.(4) Kullgren et al. consider five dimensions – “affordability, 
accommodation, availability, accessibility, and acceptability” – in their framework. (1)  
Access to care is especially challenging for patients with chronic diseases and patients 
living in rural areas, and can be further complicated by major public health challenges like the 
COVID-19 pandemic. (5) Regular access to care is especially important for the approximately 
50% of the U.S. population who live with chronic diseases(s)/condition(s), as they typically 
need more regular interactions with healthcare systems. (6) Among people living with chronic 
diseases in the United States, over 50% have experienced challenges accessing healthcare. (7) 
Further, compared to those living in urban or suburban areas, people living in rural areas are 
more likely to live geographically far from a healthcare provider, report fair/poor health, 
access healthcare less frequently, and have one or more chronic conditions. (8–11) 
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Preventive care, including screening, is important to reduce morbidity and mortality of 
chronic disease. Such care is provided by highly trained medical providers, such as licensed 
physicians, physician assistants, or nurse practitioners. Additional resources used for such 
preventive care may also include specialized equipment and testing. These resources, both 
personnel and equipment, contribute to meaningful care, but are often expensive. Further, 
such specialized resources come with additional logistical challenges: they may be difficult to 
place in rural areas, they may consume a large amount of physical space, and/or a shortage of 
such resources may exist (e.g., provider shortage). 
In this work, we will explore how industrial engineering tools can be used to 
evaluate and design aspects of healthcare systems to improve access, with a focus on access 
to care for United States veterans. Veterans typically receive healthcare at Veterans Health 
Affairs (VHA) clinical locations. As a subpopulation, veterans have several characteristics 
that can make accessing healthcare challenging. The VHA also has several unique 
organizational components that distinguish it from other healthcare providers, making policy 
and operational changes more amenable to evaluation using engineering methodologies.  
 
1.2. Engineering Tools for Evaluating Access to Healthcare 
Engineering tools can help identify and propose solutions to resolve barriers to care by 
more effectively allocating limited resources, including facilities and personnel, and by 
incorporating new services and technologies when modeling access. Models vary based on the 
dimension of access they are targeting, ranging from spatial interaction models to measure 
geographic healthcare access, (12) integer programming models to address patient 
 3 
appointment scheduling, (13) and basic statistical and economic models to analyze financial 
access. (13,14) 
Facility location models were introduced by Alfred Weber in 1929 and were applied to 
healthcare problems in later decades. (15) Facility location problems can be applied to several 
problems in healthcare, including ambulance dispatching and routing, blood bank locations, 
and emergency care services planning. Examples of facility location models applied to access 
are include considering how to locate clinic buildings and/or services to minimize the average 
distance that patients travel for a medical visit or determining the minimum number of 
facilities needed to satisfy patient needs within a geographic area.  
Mehrez et al. (1996) describe a model with a single facility optimization, which allows 
them to evaluate four different objective functions and problem structures.  (16) In their paper, 
which considers where (and whether) to build a hospital in a finite set of locations in southern 
Israel, the authors first evaluate models using iterative scenario analyses and then 
qualitatively examining model results using multi-criteria hierarchical analysis software. This 
paper clearly outlines the sociopolitical challenges related to healthcare access, including 
issues with government support, community-based social norms, and public security. 
Additionally, constraints are clear and reasonable.  The authors’ inclusion of Euclidean 
distance analyses in some of their models may oversimplify their research question, however 
their use of more precise distance measurements in two of the four models alleviates this issue 
to an extent. The major takeaway of this paper is the methodology for including subjective 
information in a facility location model, specifically when implementing a new provider 
facility. 
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In her 2011 paper, Nicoleta Serban discusses service accessibility equity using a 
space-time varying coefficient model. (17) Here, her focus on access is primarily geographic, 
but travel logistics are also considered. She accurately notes the challenge in measuring 
individual travel costs for a specific community. The model itself is a multilevel varying 
coefficient model that considers services providers which interact between time and space. 
Though such a model may be burdened by issues with computational efficiency, Serban 
utilizes penalized splines and an inference procedure for assessing the space-time varying 
coefficients. Serban applies her model to equity of utilization of financial services, stratified 
by race and income. This paper contributes to the literature through its methodology for 
addressing computational efficiency of a multilevel space-time varying coefficient model, as 
well as its inclusion of a simulation study to confirm model estimation.  
A 2005 paper by Wang and Luo adds to their two-step floating catchment area 
(2SFCA) method, first introduced in 2003. (18,19) The original 2SFCA paper considers 
includes both (a) provider supply in a given area, and (b) where the population is situated – 
effectively a ratio of provider-to-population. In their 2005 paper, the authors focus on how 
this approach can be used to address “health professional shortage areas” – geographical 
regions that have been designated as medically underserved. Such areas are often rural. In 
addition to the spatial measurements provided by 2SFCA, the authors also incorporate 
nonspatial variables via factor analysis. They integrate both aspects to indicate healthcare 
needs in a given geographical area. While their 2003 paper was effective in defining a critical 
metric (2SFCA) the 2005 paper is an appropriate and meaningful addition that considers basic 
population demographics to more wholly indicate healthcare needs. 
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Tang et al. (2017) expand on the 2SFCA method by incorporating spatial patient flows 
that model human decision behavior, including an individual’s (nonspatial) healthcare needs.   
(12) They demonstrate their model using a case of elderly patients in Taipei City accessing 
general practitioner services. They compared their enhanced model (dubbed “F2FCA”) with 
the original 2FSCA model, as well as two intermediate models that include capacity of 
services and an exponential distance-decay function. The authors’ F2FCA model is a needed 
improvement on earlier geospatial analysis that focus primarily on geographic relationships 
between providers and patients while minimizing the importance of other aspects of access. 
In their 2013 paper Mao and Nekorchuk also consider an expansion to the 2SFCA 
method by incorporating multiple transportation modes. (20) While traditional geospatial 
models typically assume a single transportation mode, Mao and Nekorchuk alleviate this 
irrational assumption by stratifying by sub-populations who use varying transportation modes. 
They illustrate their model using a case study of hospitals in Florida. Papers that consider 
multiple transportation modes for healthcare access are rare, so the work of Mao and 
Nekorchuk is certainly meaningful. Further, their paper highlights a need for more 
sophisticated transportation data and simulation analysis methods related to transportation 
modes. Nevertheless, their assumptions about how individuals choose transportation modes 
based on distance from a provider are both over-simplified and ignore patients who would 
negate care due to not having an available feasible transportation mode.  
Fahui Wang adds to his earlier contributions in developing the 2SFCA with a 2012 
review paper on optimization methods in healthcare access. (21) Key models reviewed include 
the p median problem, which seeks to minimize total travel distance or time, the location set 
covering problem (LSCP), which seeks to minimize the number of facilities needed to cover 
 6 
demand, and the center model, which seeks to minimize the maximum distance to cover all 
individuals. Such models each have their pros and cons, and Wang encourages the reader to 
understand what type of model will suit their problem most appropriately. 
Aside from facility location models, one of the most common applications of 
operations research (OR) across all industries is scheduling and this norm holds in the 
healthcare industry, especially in patient appointment scheduling. In their 2008 paper, Gupta 
and Denton provide an overview of appointment scheduling as an application of OR. (22) 
Notably, they identify four key variables that influence the performance of patient 
appointment models: (a) mapped arrival processes, (b) service processes, (c) patient and 
provider preferences, and (d) incentives and performance measures. While the former two 
variables are often considered in OR applications through probability distributions and/or 
sensitivity analyses, the latter two variables are both meaningful and can be relatively specific 
to the healthcare industry. Gupta and Denton conclude their paper with several opportunities 
for future work. One such opportunity is health system design. While this paper is over ten 
years old, health system design is still relevant today. Since this paper was published, the 
United States has adopted the Patient Protection and Affordable Care Act (the “ACA”), which 
proposes significant changes to provider reimbursement and patient insurance coverage – both 
of which impact health system design. While the ACA was under fire from an oppositional 
federal government during the Trump administration, it appears to be more likely to remain 
intact for the foreseeable future. (23) Nevertheless, there is uncertainty involved when 
designing and/or modifying health system structures, so OR tools are likely to remain relevant 
for addressing system design moving forward. 
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In a 2017 paper, Matthias Schacht proposes a reconfiguration of appointment systems 
to improve same-day access for primary care appointments. (24) Schacht uses a stochastic 
mixed-integer linear program to aid in the development of weekly schedules in a primary care 
clinic. Schacht is particularly interested in understanding how seasonality affects the 
stochasticity of patient arrivals for same-day appointments. He proves his model successful in 
a case study, however the proposed model is burdensome to arrange for a given period and the 
administrative effort in implementing and sustaining such a model seems daunting. While 
Schacht’s methodological approach provides a new perspective, his paper reminds the reader 
to consider the realistic expectations of applying OR models to address healthcare access.  
The previous scheduling papers focus on more general or primary care appointments, 
but a 2016 paper by Castaing et al. discusses a specialized application of stochastic 
programming to reduce patient wait times in outpatient infusion centers.  (25) Such 
appointments have highly variable lengths, a feature which requires uncertainty to be 
incorporated into model development and analysis. The authors develop a stochastic program 
of a Schedule Refinement Optimization Problem (SROP), as well as heuristic algorithms for 
approximating the SROP and schedules to allow cancer center staff to adjust preferences for 
patient wait times and staff idle time.  They apply their SROP to an outpatient infusion center 
to evaluate the necessary number of simulated scenarios and to compared schedules. This 
paper appropriately considers the externalities of efforts to improve patient access, namely 
operational effects on staff and resources. While their model simplifies the infusion center 
processes, the granularity is appropriate for such an application. 
While general scheduling methodologies (linear/integer programming, etc.)  remain 
somewhat consistent throughout the literature, applying those methodologies tends to require 
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individualization on a deeper, and not necessarily obvious, context compared to applications 
of facility location models. While facility location models clearly require geography-specific 
updates when applying to different areas, scheduling problems often require the incorporation 
of organizational policies, staffing requirements, and other operational constraints for them to 
be meaningful. 
OR can also be used in considering financial access to care. The first chapter of 
Operations Research and Health Care Policy (2013), written by Rauner and Scaffhauser-
Linzatti, discusses inpatient reimbursement systems in Austria.  (26) In 1997, the Austrian 
national healthcare system replaced a day-based payment structure for inpatients with a case-
based system similar to those used with diagnosis-related groups (DRGs).  The authors 
discuss optimization methods used to ensure the case-based system operates effectively. 
Optimization models are routinely run to monitor patient length-of-stay guidelines and 
hospital patient mix and volumes. Additional nonlinear optimization models are used to 
allocate variable budgets to optimize patient quality outcomes and discrete-event simulation is 
used to demonstrate competition of hospitals under case-based versus day-based payment 
systems.  While the authors themselves did not conduct all of these studies, this suite of OR 
tools helps policymakers comprehensively understand the impact of their recently-adopted 
payment system. 
In another chapter, Zaric et al. model risk sharing agreements (RSAs). (27) While their 
models focus primarily on RSAs among pharmaceutical manufacturers and insurance 
companies in single-payer health systems, RSAs are becoming increasingly common between 
providers and patients in multi-payer systems (such as the United States).  In such 
agreements, patients are typically held more financially accountable for their health and 
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associated healthcare costs. This shift of risk onto patients and/or their insurers is intended to 
incentivize patients to make more informed and appropriate healthcare decisions, especially as 
providers are seeing decreasing reimbursement schedules under the ACA. OR tools, such as 
optimization and risk analysis methods, can be effective in analyzing the impact of RSAs on 
the larger healthcare system. 
Previous research analyze access using engineering tools typically focus on one 
dimension of access (location, scheduling, etc.), but some work does attempt to incorporate 
multiple dimensions. Luo and Wang (2003) attempt to address multiple components of access 
with the 2FSCA approach, later built upon by Tang et al. (2017) and Mao and Nekorchuk 
(2013). (12,18,20) Nevertheless, these models do still miss components of access, including 
financial/insurance policy aspects.  
Policy changes can have broad impact on health system access. Simply adding more 
providers or offering different appointment times does not necessarily allow more patients to 
access care. Further, policy changes may have unintended downstream or systemic effects, 
especially when considering long-term treatment and precision health components. This work 
intends to more fully understand how policy changes systematically impact to access to  care 
and how systems engineering methods can be employed to develop this understanding.  
 
1.3. The Veterans Health Administration 
The United States Department of Veteran Affairs (VA) is a federal agency with three 
administrations: the Veterans Health Administration (VHA), the Veterans Benefits 
Administration, and the National Cemetery Administration. The VHA provides healthcare for 
eligible veterans. Veterans are eligible for VHA care if they previously served in active 
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military service and were not dishonorably discharged. Additional eligibility requirements 
based on time of service and household income also apply. Individuals who previously served 
or are currently serving in the Reserves or National Guard and completed a full period of 
active duty are also eligible. 
The VHA is geographically organized into 18 Veterans Integrated Service Networks 
(VISNs), which manage care delivery in a region. Each VISN oversees several VHA medical 
centers (VAMCs) and community-based outpatient centers (CBOCs), as well as Community 
Living Centers (CLCs). VAMCs offer two or more types of care including inpatient, 
outpatient, residential, and institutional extended care, while CBOCs provide outpatient 
services. (28,29) 
Unlike most other healthcare providers in the United States, the VHA is an integrated 
health system with a single payer; the federal government provides all VHA funding. This 
distinction can enable the VHA to encourage access to care, especially preventive care. By 
focusing resources on preventive care, the VHA will not only provide more proactive care for 
its patients, but it can also mitigate future higher costs of care. For example, the VHA is 
motivated to thoroughly screen cancer patients for malignancy so that any cases can be treated 
early, when tumors may be more easily – and cheaply – treated. Non-VHA providers are 
compensated based on volume of treatment, with more complex treatment often more highly 
compensated, and are thus less motivated to pursue preventive care.  
Compared to the general United States adult population, veterans are older; 48.8% of 
veterans are aged 65+ compared to 16.5% in the general population. (30) Veterans also are 
more likely to have chronic conditions, with 25.5% reporting one chronic condition and 
47.9% reporting two or more (a total of 73.4%). (31) For comparison, the general US adult 
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population has 18% of people reporting one chronic condition and 42% reporting two or 
more. (32) Further, veterans experience greater delays in accessing healthcare than non-
veterans. (33–35) The combination of high risk for chronic disease and challenges in 
accessing care makes how care is provided to veterans an important consideration. 
1.3.1. Recent Congressional Acts Impacting Veteran Access 
The United States Congress passed the Veterans Access, Choice, and Accountability 
Act in 2014. (36) This law set several national rules related to veterans’ access to care, 
including requiring that covered veterans receive a medical appointment within 30 days of 
request and that patients should not travel more than 40 miles to reach a VHA clinic for 
medical care. If care cannot be provided to a covered veteran within these and other access-
related requirements, the patient may choose to seek care from a medical center outside of the 
VHA. This Act also stipulates that any follow-up care within 60 days of an initial visit can be 
provided by the same medical provider. While this measure is helpful to ensure continuity of 
care, this continuity is myopic; it is helpful to improving quality of care only in the short -
term.  
In 2018, Congress passed the VA MISSION Act. (37) Several rules in the MISSION 
Act impact the work presented herein. This work adds to the requirements outlined in the 
2014 Access, Choice, and Accountability Act by providing funding specifically for non-VHA 
medical care (“community care”) that patients may utilize, as well as ensuring those visits are 
paid for by the VHA. Through this and other measures that provide funding for community 
care facilities outlined in the MISSION Act, veterans have more options when choosing 
where to receive care. 
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 The Veterans Access, Choice, and Accountability Act and MISSION Act improve 
veteran access to healthcare by lowering geographical, temporal, and logistical barriers. One 
may also argue that financial barriers are minimized because the cost of community care 
services are covered under the MISSION Act, however veterans should theoretically see no 
difference in the amount paid out-of-pocket if they were currently using the VHA for care. 
However, these acts degrade one of the chief advantages of the VHA: continuity of care, 
particularly in longitudinal care. While the acts do contain stipulations requiring sharing of 
patient information between VHA and community providers, patients lose the integration of 
services and institutional knowledge that comes with continuous care within one system.  
One solution, as indicated in the work of this dissertation, is to encourage use of VA 
medical services by distributing internal resources in ways that improve access for veterans 
and ensure that veterans can receive meaningful care. If, instead of providing financial 
coverage for non-VHA providers, the VHA uses its own personnel and other resources more 
efficiently, more veterans can maintain their care from within the VHA. 
1.4 Dissertation Summary 
This work comprises four stages: (1) using facility location and other optimization 
methods to design a healthcare network when introducing new provider options for chronic 
disease screening, (2) developing simulation tools to model how access to care is impacted 
when scheduling policies accommodate patient preferences, (3) evaluating triage strategies 
under COVID-19-related capacity restrictions, and (4) determining how treatment decisions 
impact patient access when guided by risk-based prediction models compared to current 
practice. Through these stages, we illustrate how industrial engineering can be used to 
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understand impact on veteran healthcare access when new policies or operations are 
considered.  
1.5. Key Contributions 
 In Chapter 2 we demonstrate a mixed-integer program to show how the VHA can 
distribute providers for eye care screening within a VISN to maximize the number of patients 
seen. This work considers an innovative form of care delivery – technology-based eye care 
screenings (TECS) – and demonstrates how the VHA can scale this service to improve patient 
access for chronic disease screening. This model can serve as a framework for the VHA as 
they consider new technologies, policies, and venues for care delivery.  
 In Chapter 3 we show how patient preference for appointment modality (in-person 
versus telehealth) can be considered with minimal impact to health system operations or 
patient outcomes for VHA patients with gastroesophageal reflux disease. While our case 
study indicated no negative outcomes to patient access or clinic operations, the simulation 
model could be applied to other diseases, clinic locations, and/or patient populations to 
understand the impact of considering such patient preferences, especially as healthcare 
providers across the country embrace more care provided via telehealth. 
 In Chapter 4 we present a simulation model to guide VHA clinics providing non-
emergency outpatient care as they triage patients under reduced capacity due to the COVID-
19 pandemic. This model was developed using the Ann Arbor, Michigan VHA endoscopy 
clinic as a case study, but has been applied to other VHA endoscopy clinics across the 
country. Further, while the model is designed to guide clinical decision-makers in how to best 
allocate their limited capacity during a pandemic, the model can also be used to better triage 
patients by urgency of need during non-pandemic times. 
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 Finally, in Chapter 5 we consider how the inclusion of new data-driven models 
impacts patient access for chronic liver disease patients. Machine learning and other 
predictive modeling tools have the potential to improve the accuracy of diagnoses and 
enhance the personalization of treatment plans, but little work has been done to indicate how 
including such advanced models in a care pathway may impact access. Our simulation model 





Chapter 2. Improving Veteran Access to Screening for Chronic Eye Disease 
 
2.1. Introduction 
Preventive care, including screening, is important to reduce morbidity and mortality of 
chronic disease. Such care is provided by highly trained medical providers, such as licensed 
physicians, physician assistants, or nurse practitioners. Additional resources used for such 
preventive care may also include specialized equipment and testing. These resources, both 
personnel and equipment, contribute to meaningful care, but are often expensive. Further, such 
specialized resources come with additional logistical challenges: they may be difficult to place in 
rural areas, they may consume a large amount of physical space, and/or a shortage of such 
resources may exist (e.g., provider shortage). 
 In many cases, a lower cost, more abundant resource can be used initially in place of 
higher cost, more constrained resources. For example, as we present in this chapter, ophthalmic 
technicians can screen veteran patients for chronic eye diseases within a telemedicine structure. 
Such screenings were often previously performed in-person and only by ophthalmologists or 
optometrists. When technicians instead screen these patients through telemedicine modalities, the 
Veterans Health Affairs (VHA) system benefits by reducing cost per screening, while having the 
additional benefit of locating technicians at a greater number of clinic locations than would be 
feasible from cost and space perspectives with only ophthalmologist- and optometrist-conducted 
in-person screenings. 
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 In this chapter, we present a mixed-integer program that considers how screening for 
chronic eye disease is provided in VHA clinics. In particular, we consider how to locate 
ophthalmic technicians and other eye care providers to maximize the number of patients 
screened for eye disease within the VHA, subject to a given budget, or minimize system costs, 
subject to a required number of patients who must be screened within the VHA. We also discuss 
how this model could be applied more broadly when health systems are evaluating how to 
improve patient access for chronic disease care by using various provider types. 
2.2. Background: Chronic Eye Disease Screenings for Veterans 
2.2.1. Chronic Eye Disease 
Over 1 million adults in the United States are legally blind and approximately 3.2 million 
U.S. adults are visually impaired. Furthermore, prevalence of blindness and visual impairment 
are expected to double by 2050. (38) Blindness and visual impairment affect  an individual’s life 
by making daily tasks like driving more challenging and also increasing risk for injuries and 
falls. (39) Blindness and visual impairment also have an economic impact. As stated in a 2007 
report on the economic impact of vision problems in the U.S., “the total excess monetary impact 
of visual impairment and blindness, attributable to medical and informal care, is estimated at 
$5.48 billion annually.” (40) 
The leading causes of blindness in the U.S. are primarily chronic eye diseases including 
cataract, glaucoma, age-related macular degeneration, and diabetic retinopathy. (41) A common 
risk factor among all of these diseases is age; as a person gets older, their risk for these diseases 
increases. Another common risk factor for chronic eye disease is the presence of systemic 
medical condition such as diabetes or hypertension. (42) Each of the four diseases mentioned 
affects demographic groups differently but all can be treated by optometrists and 
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ophthalmologists. Each disease also progresses uniquely, but earlier detection typically leads to 
better outcomes. (43) Because early detection can lead to better outcomes, access to timely and 
geographically proximate screening is critical, especially for patients at higher risk for chronic 
eye disease. 
Diabetes is strongly associated with vision impairment and other non-diabetic eye 
disease. (44) Patients in Veterans Health Administration (VHA) clinics have higher prevalence 
(11.4%) of diabetes compared to the general United States population (7.2%) and are also older 
(48.8% aged 65+), and thus VHA patients are at higher risk of chronic eye disease. (30,45) 
Further, veterans may experience greater delays in accessing healthcare than non-veterans as eye 
care is the third most-utilized service in the VHA and rapidly growing. (33–35) The combination 
of high risk for eye disease and challenges in accessing eye care makes how eye care is provided 
to veterans an important consideration. 
2.2.2. Veteran Eye Care and the TECS Program 
Many United States veterans receive their general healthcare from their primary medical 
care home, a VHA primary care clinic location, otherwise known as Community Based 
Outpatient Clinic (CBOC). When veteran patients visit VHA facilities, the veterans do not pay 
out-of-pocket for care, with some exceptions. Patient records are connected across VHA clinics 
through an electronic medical record system and clinics are also connected monetarily via a 
capitated system with a limited budget to care for veterans’ needs. (46,47) Because of this 
integration, clinicians may be cost-incentivized to provide high-quality care, especially 
preventative care, regardless of location. 
As the largest healthcare system in the United States, the VHA utilizes a wide variety of 
telehealth modalities for patient care. The Technology-based Eye Care Services (TECS) program 
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began in 2015 at the Atlanta VHA, the largest and one of the most complex VHA hospitals in the 
state of Georgia. The Atlanta VHA is part of Veterans Integrated Service Network (VISN) 7, 
which covers the Southeast (Alabama, Georgia, South Carolina) United States region. TECS is a 
comprehensive tele-eye screening program in which highly-trained ophthalmic technicians 
perform visual disease screenings for veteran patients in a CBOC. These screenings are usually 
performed in conjunction with a patient’s primary care visit. After the screening, optometrists 
and ophthalmologists remotely review digital ophthalmic photographs from the screening and 
provide screening assessments. If patients screen positive for disease, they are referred for 
follow-up care via face-to-face examination with an ophthalmologist or optometrist, usually in 
the VHA system. The TECS program has been deemed medically effective and of high clinical 
quality. (35)  
2.2.3. Designing a Network for Veteran Eye Screening 
VISN 7 has begun implementing the TECS program and currently has technicians 
screening patients at ten CBOCs across 2 states – Atlanta, GA; Tifton, GA; and Montgomery, 
AL. The decisions about where to place the first technicians were determined largely by 
considering pre-existing CBOC locations where patient demand existed but the VA could not 
feasibly locate an optometrist or ophthalmologist either due to space, geographic, or hiring 
constraints. These initial placements were also helpful in demonstrating efficacy of the TECS 
program. 
Moving forward, systems engineering models may be helpful to the VHA as decision-
makers consider where to add additional technicians in the region and/or where to launch the 
TECS program in other areas of the country. Such models can help the VHA meet various 
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objectives for eye care delivery, including maximizing the number of patients seen or 
minimizing costs, while ensuring access, quality, and administrative guidelines are followed. 
Some trade-offs to consider when designing a network for the TECS program are 
relatively straightforward. For example, adding a technician at a rural clinic location will 
increase system costs, but will increase the number of patients able to be screened and will also 
likely reduce the distance patients travel for screening. Additionally, more complex trade-offs 
should be considered, including a provider’s patient mix. As technicians are added to the 
network, they can screen patients, including patients previously screened by ophthalmologists 
and optometrists and new patients who would not have previously been screened. However, the 
screenings create a referral into the system which needs to be considered.  Another trade-off is 
that with TECS, ophthalmologists and optometrists may screen fewer patients, but can treat more 
patients with complex care needs, by ophthalmic surgery or disease management. 
2.3. Systems Engineering Models for Veteran Eye Screenings 
Using data from VISN 7, we developed integer programming models to design TECS 
networks in Georgia. These models were developed in collaboration between systems engineers 
and VHA clinical administrators. Each model has an objective function, decision variables, and 
constraints. The objective function indicates a value we are attempting to minimize or maximize 
by changing the values of the decision variables. The constraints indicate rules we must follow as 
we are changing those decision variables. Two models are discussed in greater detail in the next 
paragraphs. Models were coded in C++ and solved using CPLEX Optimization Studio.  
 We focus on two models for this chapter – one in which our objective function 
maximizes the number of patients we can screen within the VHA, subject to a fixed budget 
(Model A), and another in which the objective is to minimize total costs, subject to a given 
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number of patients required to be screened in the VHA (Model B). Table 1 outlines model 
details. Note that other objective functions could be used when considering designing a TECS 
network, such as minimizing the average distance patients travel to get to a clinic location. 
 
Table 1. Overview of Mixed-Integer Programming Models to Improve Veteran Access to Eye 
Care 
 Model A Model B 
Objective Maximize the number of patients 




Where to provide eye care, what type(s) of providers at each location, and 
how patients from given zip codes are “assigned” to clinic(s) 
Constraints Budget Required number of patients screened 
in the VA 
 Allowed travel distance between patient zip code and assigned clinic 
 Allowed travel time between patient zip code and assigned clinic 
 Capacity of each location for total number of providers 
 Capacity of each location for number of providers of a given type 
 Provider capacities on number of patients screened per time period and 
minimum percent capacity used 
 Required percentage of patients from each zip code required to be 
screened 
 
In each of these models, the decision variables indicate at which VHA clinic locations 
providers should be placed, what type(s) of and how many providers should be at each location, 
and the clinic location(s) to which patients from each zip code are assigned. If patients are not 
assigned to a VHA clinic, we assume they seek care from a non-VHA community provider. 
Model sets, parameters, and decision variables are outlined as: 
 
Sets 
• 𝒁: a set of zip codes, z, each with a geographic location, a non-zero integer population 
of veteran residents, and a set of distances to each of the candidate clinic locations 
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• 𝑪: a set of candidate clinic locations, c, each with a geographic location and a set of 
distances to each zip code 
• 𝑻: a set of the types of eye care providers, t, who can staff a clinic (t=1 indicates an 
ophthalmologist, t=2 indicates an optometrist, t=3 indicates a technician), and a 
capacity (the number of patients that a specific provider type can see annually) 
 
Parameters 
• 𝒃: budget, in United States dollars 
• 𝒏𝒍: a lower bound on the percentage of patients that must be assigned to in-system 
screening from each zip code 
• 𝒏𝒖: an upper bound on the percentage of patients that must be assigned to in-system 
screening from each zip code 
• 𝒓: per mile reimbursement amount for patient travel, in United States dollars 
• 𝒎: the furthest distance from a zip code to a clinic that patients are allowed to travel 
• 𝒔: the furthest time from a zip code to a clinic that patients are allowed to travel 
• 𝒒: the minimum number of total patients screened across all zip codes 
• 𝒋: a lower bound on provider utilization, 0 ≤ j ≤ 1 
• 𝑫𝒛𝒄: a set of travel distances, 𝑑𝑧𝑐, between zip code z and candidate clinic location c,  
∀ 𝑐 ∈ 𝐶, ∀ 𝑧 ∈ 𝑍 
• 𝑻𝒛𝒄: a set of travel times, 𝑡𝑧𝑐, between zip code z and candidate clinic location c,  
∀ 𝑐 ∈ 𝐶, ∀ 𝑧 ∈ 𝑍 
• 𝑷𝒛: a set of populations, 𝑝𝑧, of veteran residents in each zip code, z,  ∀ 𝑧 ∈ 𝑍 
• 𝑽𝒕: a set of patient capacities, 𝑣𝑡, that provider type t can see annually  ∀ 𝑡 ∈ 𝑇 
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• 𝑨𝒄
𝒕 : a set of annual care costs, 𝑎𝑐
𝑡 , for a provider type t to screen a patient at clinic c,  
∀ 𝑐 ∈ 𝐶, ∀ 𝑡 ∈ 𝑇 
• 𝑬𝒛: a set of flags, 𝑒𝑧, to indicate a zip code, z, is beyond the maximum allowable 
distance, m, or maximum allowable time, s, from any candidate clinic location. If 
true, 𝑒𝑧 = 1, otherwise 𝑒𝑧 = 0,  ∀ 𝑧 ∈ 𝑍 
• 𝑭𝒄
𝒕 : a set of per-provider costs, 𝑓𝑐
𝑡, to hire a provider type t to screen patients at clinic 
c for one year,  ∀ 𝑐 ∈ 𝐶, ∀ 𝑡 ∈ 𝑇 
• 𝑮𝒄
𝒕 : a set of upper bounds on capacity, 𝑔𝑐
𝑡, of provider type t at clinic c,  ∀ 𝑐 ∈
𝐶, ∀ 𝑡 ∈ 𝑇 




𝒕 : the number of patients from zip code z to visit provider t at clinic location c, 
∀ 𝑐 ∈ 𝐶, ∀ 𝑡 ∈ 𝑇, ∀ 𝑧 ∈ 𝑍 
• 𝒚𝒄
𝒕 : the number of providers of type t to staff clinic location c, ∀ 𝑐 ∈ 𝐶, ∀ 𝑡 ∈ 𝑇  
 
Several constraints are used in both models, including a limit on driving distance/time for 
patients, each provider type’s capacity for patients (with a lower-bound on capacity used), and 
each clinic location’s capacity for providers. To ensure patients from rural zip codes are 
considered appropriately, we also add a constraint that requires a minimum percentage of 
patients from each zip code who must be screened in the VHA. These constraints and objective 




Patient Capacity Requirement 
𝑗𝑡 ∗ 𝑣𝑡 ∗ 𝑦𝑐




𝑡 ∀ 𝑐 ∈ 𝐶, ∀ 𝑡 ∈ 𝑇 
 
Demand Requirement 
𝑛𝑙 ∗  𝑝𝑧 ≤ ∑ ∑ 𝑤𝑧,𝑐
𝑡
𝑡∈𝑇𝑐∈𝐶   𝑒𝑧 = 0, 𝑧 ∈ 𝑍 
0 ≤ ∑ ∑ 𝑤𝑧,𝑐
𝑡




𝑢 ∗  𝑝𝑧   ∀ 𝑧 ∈ 𝑍 
 
Provider Capacity Requirement 
𝑦𝑐
𝑡 ≤ 𝑔𝑐
𝑡    ∀ 𝑐 ∈ 𝐶, ∀ 𝑡 ∈ 𝑇 
∑ 𝑦𝑐
𝑡
𝑡∈𝑇 ≤ 𝑔𝑐     ∀ 𝑐 ∈ 𝐶 
 
Furthest Traveling Distance/Time Requirements 
∑ ∑ ∑ 𝑤𝑧,𝑐
𝑡
𝑐∈𝐶𝑑𝑧,𝑐>𝑚𝑧∈𝑍
= 0𝑡∈𝑇   
∑ ∑ ∑ 𝑤𝑧,𝑐
𝑡
𝑐∈𝐶𝑡𝑧,𝑐>𝑠𝑧∈𝑍
= 0𝑡∈𝑇   
 
Budget Requirement (Model A only) 
∑ ∑ ∑ [(𝑎𝑐
𝑡 + 𝑟 ∗ 𝑑𝑧,𝑐) ∗ 𝑤𝑧,𝑐
𝑡 + 𝑓𝑐
𝑡 ∗ 𝑦𝑐
𝑡]𝑧∈𝑍𝑡∈𝑇𝑐∈𝐶 + ℎ ∗ ∑ (𝑛
𝑢 ∗ 𝑝𝑧 − ∑ ∑ 𝑤𝑧,𝑐
𝑡
𝑡∈𝑇𝑐∈𝐶 )𝑧∈𝑍 ≤ 𝑏  
 
Minimum Number of People Screened In-System Requirement (Model B Only) 
∑ ∑ ∑ 𝑤𝑧,𝑐
𝑡










Minimize ∑ ∑ ∑ [𝑎𝑐
𝑡 ∗ 𝑤𝑧,𝑐
𝑡 + (𝑟 ∗ 𝑑𝑧,𝑐 ∗ 𝑤𝑧,𝑐
𝑡 ) + 𝑓𝑐
𝑡 ∗ 𝑦𝑐
𝑡]𝑧∈𝑍𝑡∈𝑇𝑐∈𝐶 + ℎ ∗
∑ (𝑛𝑢 ∗ 𝑝𝑧 − ∑ ∑ 𝑤𝑧,𝑐
𝑡
𝑡∈𝑇𝑐∈𝐶 )𝑧∈𝑍  
 
The model constraints reflect VHA administrative requirements, as well as goals for 
improving access to care. However, our base models primarily require that patients are assigned 
to clinics that are (a) open/have capacity and (b) are within the required driving distance/time 
from their home. Thus, patients may be assigned to a clinic that is 35 miles from their home, 
when another clinic 10 miles from their home also provides eye disease screening.  To account 
for this, we have conducted an additional analysis that considers patient behavior by including 
constraints that indicates patients must visit the closest open clinic; that is, a patient is assigned 
to whatever clinic location is both open and has the shortest distance from the patient’s home zip 
code. We demonstrate the updates to our model formulation required for this scenario in the 
following proof: 
 
Nearest Clinic Requirement Model Update and Proof 
Claim. In our previously established mixed-integer program, we decide which clinics should 
offer eye care, what provider type(s) should staff each clinic, and how patients from zip codes 
are assigned to each open clinic. We previously considered C clinics and Z zip codes. We now 
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consider for each zip code, z, an ordered set of clinics, 𝐶𝑧
∗, with each clinic denoted by 𝑐𝑧
𝑖 . 
These clinics are ordered such that clinic 𝑐𝑧
1 is the closest clinic to zip code z, clinic 𝑐𝑧
2 is the 
second closest clinic, etc. We assume no clinics are equally distant from a given zip code (that 
is, no “ties” exist in ordering clinics). The variable 𝑦𝑐 indicates if clinic c is open (where a 
value of 1 indicates the clinic is open) and the variable 𝑥𝑧,𝑐 indicates if patients from z are 
assigned to c. To ensure patients are assigned to the nearest open clinic, we add the following 
constraints to our previously established model: 
(1)     𝑥𝑧,𝑐𝑧𝑖 ≤  𝑦𝑐𝑖 , ∀𝑧 ∈ 𝑍, ∀𝑐𝑧
𝑖 ∈ 𝐶𝑧
∗ 





= 1, ∀𝑧 ∈ 𝑍 









≤ (1 − 𝑦𝑐𝑖), ∀𝑧 ∈ 𝑍, ∀𝑐𝑧
𝑖 ∈ 𝐶𝑧
∗ 
Constraint (1) requires patient zip codes only be assigned to a clinic that is open. Constraint (2) 
requires that each patient zip code is only assigned to one clinic. Constraint (3) requires that 
patient zip codes are assigned to the nearest open clinic. 
Proof. By contradiction: Suppose there exists a zip code z with patients assigned to (open) 
clinic k. Suppose there also exists some clinic, l, which is also open and closer to z than clinic 
k. 
1. By supposition and constraints (1) and (2): 
𝑥𝑧,𝑘 = 1, 𝑥𝑧,𝑙 = 0, 𝑦𝑘 = 1, 𝑦𝑙 = 1 
2. Because all 𝑥𝑧,𝑐 variables are binary by constraint (3): 
𝑥𝑧,𝑘 ≤ ∑ 𝑥𝑧,𝑖
𝑘−1
𝑖=𝑙+1














≤ (1 − 𝑦𝑙) 
Thus: 
𝑥𝑧,𝑘 ≤ (1 − 𝑦𝑙) 
1 ≤ (1 − 1) 
1 ≤ 0 
which cannot be true. 
Given the added constraints, if zip code z is assigned to a clinic, but another clinic is open and 
closer, the constraints will be violated. 
 
 Finally, we have developed an extension of Model A that considers both screening and 
follow-up care (Model A+). In Model A+, some percentage of patients require additional 
appointments (follow-up care), indicating they have screened positive for some chronic eye 
disease. The additional appointments incur both costs and appointment capacity of optometrists 
and ophthalmologists; technicians cannot provide follow-up care. To incorporate follow-up care, 
we solve two consecutive mixed-integer programs (MIPs). The first MIP is structured the same 
as Model A, which maximizes the number of patients screened, subject to a budget. Under 
Model A+, the budget in this first MIP is reduced to reflect that some patients will require 
follow-up care and thus the entire budget should not be allocated to screening patients. The 
second MIP is structured similarly to Model A, but now maximizes the number of patients who 
receive follow-up care. In this second MIP, we add a constraint that we must screen at least N 
patients, where N equals the objective function of the first MIP. We also adjust constraint values 
to reflect the capacity and costs of both screening and follow-up care. 
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 When considering the mathematical notation of Model A+, we broadly consider 𝜌, the 
probability that a patient screens positive for some chronic visual disease, and τ, the additional 
number of treatment appointments that a patient would need if screened positive. We assume (a) 
that all positive-screened patients require the same number of treatment appointments, (b) that all 
patients go to treatment appointments when there is appropriate capacity, (c) optometrists and 
ophthalmologists are both qualified/licensed to treat all chronic visual disease, and (d) that 
capacity inputs for optometrists and ophthalmologists are updated to include both their screening 
and treatment capacities (previously capacities only included screening). We update our patient 
assignment decision variables to include: 
• 𝒘𝒛,𝒄
𝒕 : the number of patients from zip code z to visit provider t at clinic location c for 
screening, ∀ 𝑐 ∈ 𝐶, ∀ 𝑡 ∈ 𝑇, ∀ 𝑧 ∈ 𝑍 
• 𝒌𝒛,𝒄
𝒕 : the number of patients from zip code z to visit provider t at clinic location c for 
treatment, ∀ 𝑐 ∈ 𝐶, ∀ 𝑡 ∈ 𝑇, ∀ 𝑧 ∈ 𝑍, where ∑ ∑ 𝑘𝑧,𝑐
𝑡
𝑡∈𝑇  𝑐∈𝐶 ≤ ∑ ∑ (𝜌 ∗ 𝜏 ∗𝑡∈𝑇𝑐∈𝐶
𝑤𝑧,𝑐
𝑡 ) ∀𝑧 ∈ 𝑍  
We updated our Patient Capacity Requirements to be: 
𝑗𝑡 ∗ 𝑣𝑡 ∗ 𝑦𝑐




𝑡  ∀ 𝑐 ∈ 𝐶, 𝑡 = 𝑇𝑒𝑐ℎ𝑛𝑖𝑐𝑖𝑎𝑛 
𝑗𝑡 ∗ 𝑣𝑡 ∗ 𝑦𝑐
𝑡 ≤ ∑ (𝑘𝑧,𝑐
𝑡 + 𝑤𝑧,𝑐
𝑡 )𝑧∈𝑍 ≤ 𝑣
𝑡 ∗ 𝑦𝑐
𝑡 ∀ 𝑐 ∈ 𝐶, ∀ 𝑡 ∈ 𝑂𝑝𝑡𝑒𝑚𝑒𝑡𝑟𝑖𝑠𝑡/𝑂𝑝ℎ𝑡ℎ𝑎𝑙𝑚𝑜𝑙𝑜𝑔𝑖𝑠𝑡 
 The cost function can be updated to reflect screening and treatment costs, with 𝛼𝑐
𝑡 
representing the cost for treatment appointments at clinic c with provider type t. 
∑ ∑ ∑ [(𝑎𝑐
𝑡 + 𝑟 ∗ 𝑑𝑧,𝑐) ∗ 𝑤𝑧,𝑐
𝑡 + (𝛼𝑐
𝑡 + 𝑟 ∗ 𝑑𝑧,𝑐) ∗ 𝑘𝑧,𝑐
𝑡 + 𝑓𝑐
𝑡 ∗ 𝑦𝑐
𝑡]𝑧∈𝑍𝑡∈𝑇𝑐∈𝐶 + ℎ ∗ ∑ (𝑛
𝑢 ∗ 𝑝𝑧 −𝑧∈𝑍
∑ ∑ 𝑤𝑧,𝑐
𝑡
𝑡∈𝑇𝑐∈𝐶 )  
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 To set our objective functions, we first allocate a portion of our budget, b, to screening 
appointments. The proportion of the budget that should be allocated to screening is represented 






𝑡 ∗ 𝜌 ∗ 𝜏)
 
 We solve our updated model in two steps. First, we solve a screening-only model, similar 
to Model A in which we maximize the total number of people assigned to screening within the 
VHA. We keep our objective function as: 
Maximize ∑ ∑ ∑ 𝑤𝑧,𝑐
𝑡
𝑧∈𝑍𝑡∈𝑇𝑐∈𝐶  
 With updated budget constraint where budget is now 𝛾 ∗ 𝑏 for screening: 
∑ ∑ ∑ [(𝑎𝑐
𝑡 + 𝑟 ∗ 𝑑𝑧,𝑐) ∗ 𝑤𝑧,𝑐
𝑡 + 𝑓𝑐
𝑡 ∗ 𝑦𝑐
𝑡]𝑧∈𝑍𝑡∈𝑇𝑐∈𝐶 + ℎ ∗ ∑ (𝑛
𝑢 ∗ 𝑝𝑧 − ∑ ∑ 𝑤𝑧,𝑐
𝑡
𝑡∈𝑇𝑐∈𝐶 )𝑧∈𝑍 ≤  𝛾 ∗ 𝑏  
 The feasibility constraints for requirements on demand, provider capacity, and furthest 
traveling distance/time can remain the same. 
 We set a value, N, to our objective value from solving this model in our first step. In the 
second step, we solve the following objective function, seeking to maximize the number of 
people treated following screening plus the number of patients screened. In this objective 
function, the number of patients screened is multiplied by a negligibly small value, 𝜈. 
Maximize ∑ ∑ ∑ (𝑘𝑧,𝑐
𝑡 + 𝜈 ∗ 𝑤𝑧,𝑐
𝑡 )𝑧∈𝑍𝑡∈𝑇𝑐∈𝐶  
 We use the cost function described above, subject to the total budget, b: 
∑ ∑ ∑ [(𝑎𝑐
𝑡 + 𝑟 ∗ 𝑑𝑧,𝑐) ∗ 𝑤𝑧,𝑐
𝑡 + (𝛼𝑐
𝑡 + 𝑟 ∗ 𝑑𝑧,𝑐) ∗ 𝑘𝑧,𝑐
𝑡 + 𝑓𝑐
𝑡 ∗ 𝑦𝑐
𝑡]𝑧∈𝑍𝑡∈𝑇𝑐∈𝐶 + ℎ ∗ ∑ (𝑛
𝑢 ∗ 𝑝𝑧 −𝑧∈𝑍
∑ ∑ 𝑤𝑧,𝑐
𝑡
𝑡∈𝑇𝑐∈𝐶 ) ≤  𝑏  
 We additionally add the following constraint to ensure we are screening N patients: 
 ∑ ∑ ∑ 𝑤𝑧,𝑐
𝑡
𝑧∈𝑍𝑡∈𝑇𝑐∈𝐶 ≤ 𝑁  
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 Solving this two-step optimization model allows us to maximize the number of patients 
who can be screened, while also maximizing the number of patients who can be treated 
following a positive screening result, subject to our model constraints. 
 
2.3.1. Data 
 Patient data includes the number of individuals from each zip code in Georgia who used a 
Georgia VHA clinic location in 2017. Data about the VA system includes information about 
clinic locations, including street addresses, current number/types of providers at each location, 
salary and equipment costs for each provider type, and capacity for additional providers. Note 
that several clinic locations in Georgia did not offer eye care at any level at the time of this study. 
We used GoogleMaps Application Programming Interface to calculate the driving 
distances and driving times from each patient zip code to each clinic location. The geographic 
centroid of each zip code was used to represent the origin for each of these distance/time 
determinations. 
 We followed Mission Act guidelines for the maximum driving distance (within 40 miles) 
and maximum driving time (within 60 minutes) for patients. (48) In our analyses, patients who 
live beyond these requirements are automatically assigned to community care outside the VHA 
system. Additional administrative data also came from the VA, including budgets and driving 
reimbursement amount. 
 When considering financial parameters, costs include direct costs of clinical operations, 
including equipment, facilities, and provider salaries. For TECS, we include both the costs of 
paying technicians to conduct in-person screening, as well as cost of optometrists or 
ophthalmologists to remotely review screening results. Each appointment scheduled within the 
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VHA incorporates screening material costs and patient driving reimbursement. Appointments 
scheduled outside of the VHA (with a community care provider) incur a fixed charge per visit. 
2.3.2. Model Analyses 
We conducted six major analyses, including: (1) examining how metrics are impacted 
when we move from current state to adding and/or redistributing providers within potential clinic 
locations; (2) considering a system without any providers currently at clinic locations; (3) 
varying the budget; (4) varying the number of patients required to be screened in the VHA; (5) 
including nearest-open-clinic constraints; and (6) including both screening and follow-up care 
requirements. These analyses and their results are outlined in Sections 2.3.2.1 – 2.3.2.6. 
For each analysis, we consider the following metrics: number of patients assigned for 
chronic eye disease screening, average distance (in miles) that patients travel for screening, 
average time (in minutes) that patients travel for screening, cost for community care, cost for 
VHA care, and total system cost. 
In all scenarios except our Current State (in the first analysis), inputs for each model 
specify that at least 10% of patients from each zip code must be screened in the VHA and at least 
80% of each provider’s capacity must be used. For Model A, a budget of $25 million is used, 
based on current VHA budgets. For Model B, at least 18,300 patients must be screened in the 
VHA, based on the Current State analysis in which we are maximizing the number of patients 
screened in the VHA. 
2.3.2.1. Current State versus Additional Providers 
In our first analysis, we maximize the number of patients screened in the VHA, subject to 
a budget, without moving the current providers or adding additional providers. In this first 
maximization problem, we do not require 10% of patients from each zip code to be seen because 
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it would be infeasible, but this constraint is included in all other analyses. Next, we allow for 
providers to be added while keeping current providers at their respective locations and solve each 
model. Under Model A, we maximize patients seen given the same budget as current state. 
Under Model B, we minimize cost while requiring at least as many patients to be screened within 
the VA as are in current state. 
For the Current State versus Additional Providers Analysis (Table 2), we see that in both 
Models A and B, we can screen more patients within the VHA than in current state when we 
consider additional providers, while remaining within budget. Additionally, the average distance 
and time traveled by patients is lower in both models compared to Current State. Critically, in 
both Models A and B (and all subsequent analyses), 10% of patients from each zip code are 
required to be screened in the VHA, which indicates Models A and B also improve geographical 
equity compared to current state. Note that 5,278 patients live beyond the VHA requirement for 
allowable driving distance and time (40 miles or 60 minutes) from any potential clinic location 
considered and are automatically assigned to community care in all analyses. 
 
Table 2. Current State versus Considering Additional Providers 
Metric Current State Model A Model B  
Number of Patients Screened in VA 18,300 75,000 29,640 
Average Distance Traveled (miles) 22.7 12.6 12.8 
Average Time Traveled (minutes) 31.6 21.0 20.3 
Screening Cost - Internal $6.1 M $20.9 M $9.0 M 
Screening Cost – Community Care $18.3M $4.1 M $15.5 M 
Total Screening Cost $24.4 M $25.0 M $24.5 M 
 
2.3.2.2. No Current Providers Required 
In our next analysis, we compare metrics for both models when we keep the clinic 
locations and patient counts/locations the same, but do not consider any of the current provider 
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staffing levels (Table 3). Compared to when these providers are required to staff the locations 
where they currently work, our models show improved objectives: Model A yields over 7,000 
more patients seen within the VHA for the same budget compared to when current providers are 
required; Model B demonstrates savings of over $1 million relative to current providers being 
required, while still seeing more patients than current state. These improvements are largely from 
including more technicians in locations currently staffed by ophthalmologists. 
 
Table 3. No Current Providers Required 











Number of Patients Screened in VA 82,278 +7,278 28,980 -660 
Average Distance Traveled (miles) 14.7 +2.1 12.9 + 0.1 
Average Time Traveled (minutes) 23.3 +2.3 20.5 + 0.2 
Screening Cost - Internal $22.7 M +$1.8 M $7.6 M - $1.4 M 
Screening Cost – Community Care $2.2 M -$1.9 M $15.6 M + $0.1 M 
Total Screening Cost $24.9 M - $0.1 M $23.2 M - $1.3 M 
 
Figure 1 depicts maps that represent the results of our first two analyses. We see that by 
moving from the current state to adding more providers any model, the number of patients 
screened in the VHA across Georgia increases. Note that when we do not require any current 







Figure 1. Map Representation of Model Results 
 
 
2.3.2.3. Impact of Budget 
For the third analysis we consider only model A (maximize patients screened) and 
increase the budget by $2.5 million and $5 million to understand how budget impacts the 
maximum number of patients we can screen in the VHA. We next evaluate the impact of budget 
by increasing budget by $2.5 million and $5 million. These analyses were conducted only for 
Model A. The results (Table 4), indicate that varying the budget impacts several metrics, 
including number of patients screened in the VHA, average distance/time traveled, and per 
patient cost. As the budget increases, we are able to screen more patients. Interestingly, as the 
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budget is increased, the average distance/time traveled increases as well. We review this 
relationship in our discussion.  
 








Number of Patients Screened in VA 75,000 83,966 83,831 
Average Distance Traveled (miles) 12.6 20.6 23.4 
Average Time Traveled (minutes) 21.0 29.5 32.7 
Screening Cost - Internal $20.9 M $25.6 M $28.0 M 
Screening Cost – Community Care $4.1 M $1.9 M $1.9 M 
Total Screening Cost $25.0 M $27.5 M $30.0 M 
 
2.3.2.4. Impact of Required Number Screened in the VHA 
For the fourth analysis, we consider only model B (minimize cost) and increase the given 
number of patients required to be screened in the VHA to 30,000 and 40,000 patients to 
understand how this requirement impacts the overall cost to the system. The results of this 
analysis (Table 5) indicate that increasing the required number screened impacts the average 
distance/time traveled, and the per patient/system costs. The average distance/time traveled 
decreases as required number of patients screened increases, largely because the additional 
patients screened will be assigned from zip codes that are geographically near clinic locations. 
Assigning patients who live near clinics also allows the model to assign many more patients 
overall than the minimum number required to screen because if a provider is already at a location 
and has capacity to screen patients, it is cheaper to screen patients in the VHA instead of sending 
them to community care. 
 
 35 
Table 5. Impact of Required Number Screened (Model B) Analysis Results 
 Required Patients Screened in VA 
Metric 18,300 30,000 40,000 
Number of Patients Screened in VA 29,640 30,900 40,980 
Average Distance Traveled (miles) 12.8 12.0 10.2 
Average Time Traveled (minutes) 20.3 19.5 17.7 
Screening Cost - Internal $9.0 M $9.3 M $11.9 M 
Screening Cost – Community Care $15.5 M $15.2 M $12.6 M 
Total Screening Cost $24.5 M $24.5 M $24.6 M 
 
2.3.2.5. Requiring Patients to Visit the Nearest Open Clinic 
In the fifth analysis, we consider model A, but add constraints that require patients to be 
screened at the clinic location that is both open and has the shortest distance from their home zip 
code. When constraints are added to require patients to visit the nearest open clinic, we see that 
fewer patients are screened within the VHA, compared to the baseline results of Model A (Table 
6). Interestingly, the average travel distance and time both increase when these constraints are 
employed, largely because there are fewer providers assigned to staff clinics within the VHA 
system. Also, one may note that provider utilization is at 100% for all providers under Model A 
under baseline conditions; with the open nearest clinic constraints used, several providers are at 
less than 100% utilization. 
 
Table 6. Impact of Nearest Open Clinic Constraints (Model A) 
 
 
 Nearest Open Clinic Constraints 
Metric Without Constraints  With Constraints 
Number of Patients Screened in VA 75,000 66,806 
Average Distance Traveled (miles) 12.6 13.2 
Average Time Traveled (minutes) 21.0 21.5 
Screening Cost - Internal $20.9 M $18.8 M 
Screening Cost – Community Care $4.1 M $6.2 M 
Total Screening Cost $25.0 M $25.0 M 
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2.3.2.6. Considering Screening and Follow-Up Care 
In Model A+, we solve two consecutive MIPs, the first that maximizes the number of 
patients screened and the second which maximizes the number of patients who receive follow-up 
care. In the second MIP, we use the objective value of the first MIP as a lower-bound constraint 
on the number of patients who must be screened. 
When we consider both screening and follow-up care in our model using Model A+, we 
see a decrease in the number of patients screened compared to Model A which considers 
screening only (Table 7). Note that Model A+ uses the same budget as Model A, so one can 
understandably assume that fewer patients will be screened because provider resources are now 
being used for follow-up care. Note that when we compare to baseline (maximizing patients 
screened with no additional providers), Model A+ still allows for screening an additional 9,000 
patients while remaining within the $25 million budget, as well as providing follow-up care to 
over 2,000 patients.  
 
Table 7. Impact of Incorporating Follow-Up Care 
 
Metric Screening Only 
(Model A) 
Screening + Follow-
Up (Model A+) 
Number of Patients Screened in VA 75,000 27,461 
Number of Patients Receiving Follow-up Care in VA - 2,179 
Average Distance Traveled (miles) 12.6 13.2 
Average Time Traveled (minutes) 21.0 20.8 
Care Costs - Internal $20.9 M $8.6 M 
Care Costs – Community Care $4.1 M $16.0 M 
Total Care Cost $25.0 M $24.7 M 
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2.3.2.7. Additional Note 
Note that we also conducted analyses in which the allowable travel distance was varied. 
However, these analyses resulted in negligible variation in metrics. This lack of variation is 
largely due to the model rarely assigning patients to geographically distant clinics because 
driving reimbursement is considered in cost calculations and total costs are either constrained by 
a budget (Model A) or are being minimized as an objective (Model B). 
2.4. Discussion 
The results of the mixed-integer program for chronic eye disease screening in veterans 
can inform a broader understanding of how healthcare networks can be organized and how 
decision-makers may consider trade-offs. Additionally, we show how systems engineering tools 
can be used in both designing new healthcare networks and evaluating how modifications to 
existing healthcare networks impact key outcomes. 
When making changes to an existing healthcare network, the systemic impact to patient 
access is not always intuitive. For example, when considering the impact to distance or time 
traveled in our chronic eye disease screening model, increasing the budget or increasing the 
required number of patients screened in the VHA yields a greater average travel distance/time. 
While one may think a substantial budget increase could decrease a metric like driving time, our 
example results in an increase because more patients from rural areas are being screened and still 
need to travel a considerable distance. However, if the VHA instead implemented more potential 
clinic locations (beyond the 28 locations considered in this example) for rural patients and/or 
considered using traveling technicians, the travel distance/time for patients may decrease when 
budget is increased. In such a scenario, shifting the budget to these alternative resources then 
may inhibit the number of providers who can be hired at urban locations, so fewer urban patients 
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may be screened in the VHA. While a perfect solution may not exist, the tools discussed herein 
help decision-makers more fully understand how the design of their system impacts patient 
access. 
Our models have some limitations. For example, we assign patients to specific providers; 
in reality, patients may prefer which provider(s) or location(s) they would like to visit. 
Additionally, while we attempt to include as many realistic constraints and parameters as 
possible in these engineering models, we typically cannot include all aspects of a scenario. 
Nevertheless, these tools can help guide decisions to understand where to consider future 
locations that may improve patient access while meeting several system requirements and patient 
constraints. 
2.5. Generalizing Our Approach 
 In the chronic eye disease screening mixed-integer program described in previous 
sections, we sought to improve access to a healthcare service for veterans. We can use this 
specific model to consider a more generalized framework in which we seek to best align patients 
with providers and/or resources. Broadly, we can classify patients and providers into two or more 
levels and seek to align patients with providers who can best meet their needs. 
 Provider “levels” include two or more components of a healthcare providing organization 
that a patient may encounter. These components could be clinician providers, diagnostic or other 
tests, or medical equipment. Herein, we will focus on clinical providers, however, we will also 
discuss how other resources may be similarly considered in later paragraphs. We focus in 
particular on provider groups that offer similar types of frontline care but have different costs 
and skill sets. 
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For example, consider the eye care screening mixed-integer program model discussed in 
the previous sections. In this model, chronic eye disease screening was previously performed by 
either an ophthalmologist or an optometrist in a face-to-face visit. Each of these providers is 
licensed to provide eye disease screening, however both could provide services beyond 
screening, with an ophthalmologist providing even more services, like surgery, than an 
optometrist. We consider these providers as two levels of care available to a patient seeking an 
eye screening. Each provider level has an associated cost and supply, with the most specialized 
level (here, the ophthalmologist) tending to have the highest cost and lowest supply. Compared 
to the ophthalmologist, an optometrist would almost certainly be less expensive for frontline 
care, such as screening. If we move one step further, we can consider the TECS program 
described previously. The TECS program effectively adds a new provider level to the system’s 
offering for chronic eye disease screening. 
We can also divide patients into levels, with each level indicating the most appropriate 
“level” of services needed. Considering eye disease, we may have a group of patients who are 
unsure of their eye disease diagnoses and would benefit most from a screening, other patients 
with mild to moderate eye disease that can be monitored and cared for by an optometrist, and 
still other patients with severe eye disease requiring complex care from an ophthalmologist. 
Patients with less complex needs could use either providers who offer only frontline care or 
those providers who offer more in-depth care. In other words, a less-complex patient could see a 
highly-specialized or a less-specialized provider. 
One can consider non-eye care settings for this hierarchical care framework. For 
example, colon cancer screening, which will be discussed in more detail in future chapters, has 
many levels of care and certain patients are best suited to receive care at one of those levels. (49) 
 40 
For patients who have the highest risk for colon cancer, including disease history, a colonoscopy 
procedure provided by a gastroenterologist may be recommended. Alternatively, patients at low 
risk of colon cancer may be recommended to conduct an at-home fecal test, requiring fewer 
clinical resources and less patient burden. (50) Patients at moderate risk may still be 
recommended to receive a colonoscopy but not as frequently as those in the high-risk category. 
(51) In this brief description, we can see provider resource levels emerging (frequent 
colonoscopy, less-frequent colonoscopy, fecal testing), with patient risk levels aligning to each.  
 When considering how to implement a hierarchical healthcare network, we could attempt 
to match patients with providers at the same level. That is, more complex patients would be 
assigned to highly-specialized providers, moderately complex patients would be assigned to 
providers at a moderately-specialized level, and so on. Perfectly matching groups of patient 
demand and provider supply may be extremely challenging, however, due to initially unknown 
patient needs, and restrictions on the geographic locations where providers are willing to 
practice, as well as capacity and budget limitations. As we account for such real-world 
complexity in the system and patient population, we add these restrictions in our model. 
Constraints exist from the patient perspective, including patient preferences about providers, how 
far they are willing to travel, and their abilities to afford care. From the healthcare system 
perspective, one can consider where provider resources may be located, physical constraints on 
provider capacity, and how the system defines its patient catchment area. 
As more of this complexity is considered, we consider trade-offs between different goals 
as we specify our key objective. For example, if we seek to minimize the system’s cost, we may 
not be able to see as many patients or patients may have to travel a greater distance for their care. 
Conversely, if our goal is to see as many patients as possible, our costs will likely increase. 
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Systems engineering provides methods and tools that allow us to quantitatively consider such 
trade-offs.  
 Systems engineering tools are helpful for designing and evaluating provider networks. 
Key tools include linear programming, including integer and mixed-integer programming, and 
simulation models. (52–57) Systems engineers, in collaboration with administrative decision-
makers, can use these tools to develop models that represent real-world scenarios. Such models 
can have meaningful results that inform operationally feasible decisions. 
While lower cost alternatives do provide several benefits, decision-makers must ensure 
that patients’ quality of care is maintained at an appropriate level compared to the care received 
with the highly specialized resource. If chronic disease screening is to be conducted by a less-
specialized provider, screening options with this provider should still be of high quality and 
patients who use such providers should have equitable health outcomes to patients screened by 
highly-specialized providers. 
Healthcare networks designed with hierarchical provider options help improve patients’ 
access to frontline care, as shown in the TECS example. Prioritization may be set to improve 
access for particular patient subpopulations. For example, our case study enforces a minimum 
percentage of patients from all zip codes to be screened and restricts the maximum distance and 
time patients can drive to reach a clinic. This improves access for rural patients by requiring the 
network to have a geographically accessible location for most patients. Improved access to 
frontline care can improve patient outcomes by determining disease status, thus improving 
opportunities for patient education and treatment planning. 
 Hierarchical healthcare networks may be challenging to implement in practice. Ideal 
implementation opportunities include an existing healthcare system, like the VHA, with many 
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geographically-dispersed care locations, distributing providers and other resources to improve 
access. Another example is an integrated health system attempting to expand ownership of 
clinical locations and considering new acquisitions. Both scenarios benefit from evaluating how 
to locate different types of providers to maximize patient access. 
2.6. Conclusion 
Systems engineering tools like mixed-integer programs can potentially improve patient 
access to care by establishing clinical locations geographically near patients and by distributing 
providers and other resources to appropriately meet patients’ needs. Further, these tools can 
facilitate implementing such networks, both in designing networks and evaluating them to 
understand how patient access may be impacted when operational or policy changes are made. 
Partnerships between engineering professionals and clinicians, especially administrative decision 
makers, are critical to fully understanding the details of a specific system and how engineering 
tools can be employed. 
The approach presented in this chapter can be extended to other applications. First, other 
specialties besides ophthalmology can be considered, especially those using frontline screening 
as a common entry point to care and those for which telehealth has already been shown to be an 
effective care modality, like dermatology. Additionally, these concepts could be applied to non-
human resources such as medical equipment and testing. Finally, these models could be 
employed outside the VHA, although VHA’s highly-integrated, cost-savings-incentivized 
organizational structure does lend itself particularly well to hierarchical networks. 
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Chapter 3. Simulating Appointment Scheduling Policies to Consider Clinical Need 
Versus Patient Preference for Telehealth 
 
3.1. Introduction 
Healthcare providers are increasingly using telehealth as an option for interacting with 
patients. (58) Telehealth can take many forms, including remote monitoring of intensive-care 
patients’ clinical status and physicians conferencing via telephone to discuss complex patients. In 
some medical specialties, like gastroenterology, clinicians have begun to use synchronous video 
to meet with patients to replace or complement in-person appointments. (59) The use of such 
remote visits increased due to precautions related to the coronavirus pandemic that began 
impacting the United States in 2020, and continued use of telehealth is expected post-pandemic. 
(60) While some appointments may benefit from or necessitate meeting in-person, video visits 
may be effective alternatives for other appointments. Moreover, some patients may prefer a 
telehealth visit because an in-person visit may require them to travel a long distance, is more 
challenging to fit in their schedule, exposes them to risk of infection from other patients and 
healthcare providers, or other reasons. 
 Telehealth can improve access to care for patients. Geographic distance is a key barrier to 
care, especially for people living in rural areas and/or those who do not have access to reliable 
transportation. (1,61,62) When appropriately implemented, telehealth can reduce the distance 
patients need to travel in order to interact with the healthcare system. By decreasing travel, 
patients also save time otherwise spent on getting to and from appointments. This saved time 
may allow patients to better accommodate visits because they can take less time off of work or 
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do not need to find childcare, which improves access to care from a logistical perspective. In a 
study of the impact of telehealth in inflammatory bowel disease (IBD), 80% of patients saved at 
least one half-day of driving by participating in a telemedicine visit. (63) Finally, telehealth has 
the potential to lower costs for a healthcare system, the savings from which can be passed on to 
patients. (13) These savings can mitigate patients’ financial barriers to care. Telehealth lowers 
cost of care by using fewer physical resources and sometimes requiring fewer clinical/nonclinical 
staff members, including medical assistants, desk staff, and environmental services. 
 As telehealth has become more common, researchers have sought to understand patients’ 
perceptions of telehealth. In a 2019 patient survey, 66% of patients reported being willing to use 
telehealth. Telehealth interest varies across age groups with older patients tending to be less 
interested in using it. (64)  However, the same 2019 survey found that 52% of patients aged 65 or 
older are willing to use telehealth. Among older adults who have had a telehealth visit, more than 
half viewed in-person visits to have better overall quality of care compared to telehealth. (65) In 
gastroenterology, a study of the effectiveness of telehealth as an option for IBD visits found that 
85% of patients reported their care was as good as it would have been in person. (63) 
 As clinical decision-makers incorporate telehealth options into their systems, simulation 
can be valuable for understanding how to effectively incorporate this modality. (54,66–68) 
Simulation is often used to guide healthcare decision-makers in evaluating alternatives, often by 
incorporating uncertainty. Discrete-event simulation is helpful in scenarios in which patients 
arrive and interact with a healthcare system via a set of clinical encounters. We add to this 
literature by applying simulation to a new context area that covers patient preferences for 
telehealth. Specifically, our model demonstrates scheduling policies that balance these patient 
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preferences with clinical needs when scheduling appointments within the operational constraints 
of a clinic. 
3.2. Problem Statement 
As we demonstrate how simulation can be used to consider patient preference for 
telehealth, we focus on patients with gastroesophageal reflux disease (GERD) throughout this 
chapter. GERD is the most common gastrointestinal (GI) diagnosis in outpatient GI clinic visits 
in the U.S., with approximately 20% of adults reporting at least weekly GERD symptoms. (69) 
The clinical presentation of GERD primarily involves heartburn and acid regurgitation. GERD 
symptoms may also indicate more serious diagnoses like Barrett’s esophagus and esophageal 
stricture. These diagnoses may be evaluated using additional testing such as upper endoscopy. 
Endoscopies occur if a provider determines a patient’s symptoms require serious attention and/or 
if a patient visits a GI provider several times. GERD is an effective diagnosis to model for our 
problem context because it may involve care from multiple provider types (primary care and 
specialty care) and many GERD appointments can be conducted either in-person or via 
telehealth, as discussed further later in this section. 
We evaluate GERD patients interacting with the Veterans Affairs (VA) Healthcare 
System gastroenterology clinic in Ann Arbor, Michigan. This care setting is ideal for conducting 
a simulation because, as an integrated healthcare delivery system, both VA primary care and GI 
providers belong to the same health system. Thus, patients can more easily be transferred 
between the two provider types. 
GERD patients interact with the VA via several appointments as outlined in Figure 2. 
Patients tend to treat GERD symptoms at home with over-the-counter therapy prior to seeking 
clinical care. They then typically visit a primary care provider (PCP) or, less commonly, self-
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refer to a GI doctor. Regardless of provider type, a patient’s first visit will be face-to-face (F2F) 
so providers can conduct physical examinations and in-person testing. After patients complete 
each visit they can either exit the system (either because their symptoms have been adequately 
treated or are lost to follow-up) or move to a future appointment. Most return visits have a 
specific time range for follow-up (generally 2-8 weeks). This range can be considered a 
clinically ideal range for their next appointment. We consider appointments scheduled within 
this range to be “in-range” and those outside of it to be “out-of-range.” 
Figure 2. Patient flow through GERD-related appointments 
 
Patients visiting a PCP can be referred to a GI doctor after any appointment, and patients 
can be referred by their provider directly for an endoscopy if their symptoms indicate this would 
be clinically valuable. Patients may “no-show” for any appointment, in which case they are 
rescheduled for an appointment with the same provider and of the same type (F2F or telehealth). 
In our simulation logic, patients are dismissed from the system if they “no-show” three times 
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over the duration of care. Aside from the first appointment with each provider type (PCP and GI) 
and the fourth GI appointment (endoscopy), the simulation assumes that all appointments can be 
conducted either F2F or via telehealth. Telehealth has been deemed to be an appropriate 
alternative to F2F visits for the appointments considered here, with no meaningful difference in 
quality of care.  
3.3. Simulation Model 
We modeled patients flowing through GERD-related clinical visits using discrete-event 
simulation. The simulation was coded and run in C++. The model is initiated with a set of 
providers, some of whom are primary care providers (PCPs) and some of whom are 
gastrointestinal (GI) specialists. Each provider has a given weekly capacity for number of face-
to-face (F2F) and telehealth visits. In each replication, we randomly generate a stream of weekly 
patient arrivals that are Poisson distributed. Patients either seek care from a PCP or self-refer to a 
GI doctor. Each patient also has a preference for telehealth or face-to-face appointments and the 
probability of a patient preferring telehealth is based on the patient’s geographic distance from 
the clinic. Patients who live “near” a clinic location (within 40 miles) have a 50% probability of 
preferring telehealth; 100% of those who live “far” from a clinic location prefer telehealth. 
 Patients flow through care for GERD and either do not attend a visit and are immediately 
rescheduled for the same visit (no-show) or do attend the visit. Patients who attend visits are 
scheduled for their next appointment based on a scheduling policy, as described in Section 3.3.2. 
The probability of which appointment is next needed is indicated in a transition probability 
matrix (example included in Appendix A). The transition probability matrix values are based on 
historical data from the Ann Arbor VA GI clinic. 
 48 
 Our base unit of time is weeks. The simulation is run over 52 weeks unless otherwise 
noted. To calculate minimum number of replications needed, we use appointment lead time as 
our metric of interest, with a standard error of 0.2 weeks, 95% confidence interval, and an initial 
replication size of 10. With baseline (BL) inputs and scheduling patients without regard for 
appointment modality preference, we find the minimum number of replications to be 39.8. (70) 
Our model processes in under one minute with 100 replications in most cases, so we increased to 
100 replications for all analyses. 
 
3.3.1. Model Input Parameters 
We include several deterministic and stochastic input values for our model. Input values 
were derived from historical data, VA operations, and expert clinical opinions. A list of inputs is 
included in Table 8. Note that weekly provider capacities are specific to GERD patients. That is, 
we consider providers to only see 3 GERD patients via F2F appointments and 4 GERD patients 
via telehealth each week, but they may be seeing several other patients not included in this 
analysis. 
 
Table 8. Simulation model inputs. 
Parameter Baseline Value Source/Description 
Number of PCPs 2 VA operations-Ann Arbor VA GI 
clinic 
Number of GI doctors 2 VA operations-Ann Arbor VA GI 
clinic 
F2F appointment weekly capacity per 
provider (PCP or GI) 
3 VA operations-Ann Arbor VA GI 
clinic 
Telehealth appointment weekly capacity 
per provider (PCP or GI) 
4 VA operations-Ann Arbor VA GI 
clinic 
Probability of next appointment 
type/probability of system exit 
Varies based on 
current 
appointment 
Historical data-Ann Arbor VA GI 
clinic 
No-show rate (includes cancellations) 0.2 Historical data-Ann Arbor VA GI 
clinic 
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Average weekly new patient arrivals to 
PCP 
5 Historical data (Poisson 
distribution with λ=5) 
Average weekly new patient arrivals to 
GI providers 
7 Historical data (Poisson 
distribution with λ=7) - Ann Arbor 
VA GI clinic 
Proportion of patients who live far from 
clinic (defined by VA guidelines for 
“near” vs “far”) 
0.014 Historical data-Ann Arbor VA GI 
clinic, patients who live > 40 miles 
from clinic are considered “far,” 
all others considered “near” 
Probability of patient preference for 
telehealth vs. F2F visits 
0.5 for “near” 




3.3.2. Scheduling Policies 
When a patient enters the system, they are scheduled for their first appointment with 
either a PCP or GI provider. Because all first appointments must be F2F, the simulation finds the 
first available F2F appointment with the appropriate provider and schedules the patient with a 
provider of that type. Once a patient has been scheduled with any type of provider, they are 
always seen by that provider for the appropriate appointments; that is, a patient is seen by at most 
one PCP and at most one GI provider. 
After patients complete each visit, they are scheduled for a next appointment. When 
determining the patient’s next appointment, we follow a policy which considers three 
parameters: patient’s preference for appointment modality (telehealth vs. F2F), a range of time 
when the next appointment is clinically indicated (“in-range” vs. “out-of-range”), and provider 
available capacities. Unless otherwise noted, the ideal range of a next appointment is 2-8 weeks. 
Exceptions to this range include the patient’s first appointment with any provider and an upper 
endoscopy (final GI visit), which are scheduled in the next open slot. Patients who no-show are 
immediately re-scheduled with the same provider for the next available appointment of the same 
type they should have attended. Patients see at most one PCP and one GI provider; that is, they 
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are scheduled with the same provider for each visit offered within the set of PCP or GI 
appointments. 
 We construct a scheduling policy by combining an in-range policy (lettered A, B, C) and 
an out-of-range policy (numbered 1, 2) from Figure 3. For example, if we are following policy 
C2 and a patient who prefers telehealth needs a new appointment, we first attempt to schedule 
the soonest possible telehealth appointment within the next 2-8 weeks. If no telehealth 
appointments are available in this time frame, we then attempt to schedule the soonest possible 
F2F visit with the appropriate provider. If no appointments of any type are available in-range, we 
then schedule the patient for the soonest possible out-of-range appointment of their preferred 
type with the appropriate provider. 
 
Figure 3. Scheduling policies used in the model 
 
If no appointments are available out-of-range or if the patient’s next appointment will be 
beyond the time horizon (e.g., it is week 52 of a 52-week analysis), we assume the patient is 
scheduled for an appointment beyond the horizon. These instances are tracked, but patients are 





A. First available appointment – any modality type (F2F vs. telehealth) 
B. First available appointment – preferred modality type only 
C. First appointment available of preferred modality type. If no in-range appointment of 
preferred modality type available, first available appointment of any type 
Out-of-range Policies 
1. First available appointment– any modality type 
2. First available appointment – preferred modality type only 
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3.3.3. Metrics 
We track several metrics including lead time to first appointment, percentage of patients’ 
appointment modality preferences met, provider utilization, number of patients who complete 
care, and number of out-of-range appointments. Lead time is calculated as the number of weeks 
between a patient “arriving” in the simulation to their first scheduled appointment. Percentage of 
modality preferences met considers the number of appointments could be scheduled for either 
F2F or telehealth (all appointments except the first visit with each provider and endoscopy) as 
the denominator and the number of those times in which a patient’s preferred modality was 
scheduled as the numerator. Appointments that must be conducted F2F are not included in the 
denominator of total appointments when considering percent of modality preferences met. 
Provider utilization is the percentage of providers’ available appointment capacities that are used 
for patient visits. The average number of out-of-range appointments is a count of the number of 
appointments that were scheduled outside of the clinically-ideal range, averaged across 
replications. 
3.4. Analyses 
We present several scenarios in considering patient preference for appointment modality 
when scheduling GERD patients. For these scenarios, we use scheduling policy C1 unless 
otherwise noted. Policy C1 indicates that when scheduling a patient in-range, we attempt to 
schedule the patient for the first available appointment of their preferred type. If no preferred 
appointments are available in-range, we attempt to schedule the patient for their non-preferred 
type in-range. If no appointments are available in-range, we schedule the patient for the first 
available appointment of any type out-of-range. 
 52 
The four scenarios considered in this analysis include: (1) impact of a higher proportion 
of patients being far from clinic, (2) impact of patient arrival rates, (3) comparison of changing 
the number of providers versus changing provider capacity, and (4) comparison of scheduling 
policies. Additionally, we conduct sensitivity analyses to understand the inputs that have the 
greatest effect on key metrics. Table 9 lists output metrics when using the baseline inputs listed 
in Table 8 under policy C1.  
 
Table 9. Baseline metric values, policy C1 
Metric Value  Metric Value 
Percent modality 
preference met 
99.98%  Telehealth 
utilization 
48.36% 
Lead time 2.94 
weeks 
 Overall provider 
utilization 
70.12% 
Patients seeking care 355.23  F2F utilization 99.13% 
Patients completing care 299.01  Out-of-range appts. 119.06 
 
3.4.1. Scenario 1: Distance to Care 
In the first scenario, we vary the percentage of patients who live “far” (>40 miles) from 
the clinical location. In all analyses, 100% of patients who live far from care prefer telehealth 
appointments and 50% of patients who live near care prefer telehealth appointments. In our 
baseline analyses, 1.4% of patients live far from care, based on historical data of GERD patients 
at the Ann Arbor VA. Given that many other systems will have different proportions of patients 
who live far from care (or other demographics that influence likelihood of preferring certain 
appointment modalities), we vary the percentage of patients who live far from 0-50% to 
understand the impact on metrics. 
 Results from Scenario 1 are included in Table 10. We see that as more patients are far 
from care, overall (OA) provider utilization increases, largely due to increased telehealth 
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appointment. As a greater proportion of patients are far from care, lead time decreases. This 
outcome is a result of more patients preferring, and thus being scheduled for, telehealth 
appointments according to policy C1. The relative increase of telehealth utilization frees more 
F2F appointments, which patients newly entering the system can use. Additional metrics that 
indicate clinical impact to patients like lead time and number of out-of-range appointments are 
not significantly impacted by changing the percentage of patients who live far from care. 
 In this scenario (also Scenarios 2 and 3), policy C1 accommodates patient preference 
appropriately, thus the percentage of modality preferences met is greater than 99% in all 
instances. This occurs because appointment capacity typically exists so patients get their 
preference for appointments that can be conducted in multiple modalities. Because of this, we do 
not report on percent preferences met for Scenarios 1-3. 
 
Table 10. Impact of distance to care on utilization and lead time 
 % of Patients who live far (>40 miles) from care 
Metric 0% 1.4% 
(BL) 
2.8% 10% 25% 50% 































































3.4.2. Scenario 2: Patient Arrival Rates 
In our baseline analyses, we model five patients arriving each week seeking care from a 
PCP and seven each week self-referring to a GI doctor, with each arrival rate being Poisson 
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distributed. To understand how different patient arrival rates impact the system, we vary the PCP 
patients from 3-9 arrivals per week and the GI patients from 5-9 arrivals per week. 
 Table 11 shows the results from this scenario analysis. The general relationship between 
patient arrival rates and utilization is direct; as more patients arrive each week, utilization 
increases. The number of patients who self-refer to GI has a lesser impact on utilization than the 
number of patients who visit a PCP first. Lead time and patient arrival rates also have a direct 
relationship. However, when the PCP patient arrival rate decreases by 2 per week, the difference 
in lead time is statistically insignificant. All other changes to arrival rates presented here do 
indicate a significant difference in lead time. Similarly, the number of out-of-range appointments 
is impacted by arrival rate via a direct relationship. When arrival rates are either increased or 
decreased by 2 patients per week, the number of out-of-range appointments is significantly 
impacted. This relationship remains whether patients enter the system via PCP appointment or 
via self-referral, though changes in the arrival rates of self-referred patients has a larger impact 
on the number of out-of-range appointments compared to changes in arrival rates of patients 
arriving to a PCP appointment. 
 
Table 11. Impact of patient arrival rates on utilization and lead time 
 Weekly Patient Arrivals 























































































3.4.3. Scenario 3: Number of Providers vs. Provider Capacity 
As health systems incorporate telehealth into care, they may consider how to adjust 
staffing. In this scenario we vary the number of providers. At baseline we have two PCPs and 
two GI doctors. We vary the number of each provider from 1-4. We consider how changing the 
number of providers compares to changing provider capacities. At baseline each provider has 
weekly capacity for four telehealth and three F2F GERD visits. We consider instances where 
both PCPs have a weekly capacity for two telehealth and one F2F visit (“lower capacity”), and 
where one of the two PCPs have a weekly capacity of seven telehealth and five F2F visits 
(“higher capacity”). We conduct the same set of capacity changes with GI doctors.  
Tables 12 and 13 present analyses of the impact of provider count and capacity, 
respectively. Logically, as we decrease the number or capacity of providers, utilization and lead 
time increase; conversely, those metrics decrease when increasing provider count or capacity. 
When considering lead time, changing the number of providers in these scenarios has a greater 
impact than changing the capacity of providers. We see the largest impact when going from two 
to one PCP, with an increase in lead time of over 5 weeks.  
Changing provider counts or capacity has a significant impact on the number of out-of-
range appointments, with changes to PCP provider counts/capacity having a greater impact 
compared to GI. Of note, removing one PCP nearly triples the number of out-of-range 
appointments; removing one GI provider more than doubles this number. Because we are so 
often able to meet patients’ preferences with Policy C1 and our current provider 
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counts/capacities, increasing these values has a lesser impact on number of out-of-range 
appointments compared to decreasing counts or capacities. 
 
Table 12. Impact of number of providers on utilization and lead time 
 Provider Count 
Metric 2 PCP, 2 
GI (BL) 
1 PCP, 2 
GI 
4 PCP, 2 
GI 
2 PCP, 1 
GI 
2 PCP, 4 
GI 



















































Table 13. Impact of provider capacity on utilization and lead time 
 Provider Capacity 





Cap.), 2 GI 
2 PCP 
(High 
Cap.), 2 GI 
2 PCP, 2 
GI (Low 
Cap.) 
















































78.40    
±8.55 
 
3.4.4. Scenario 4: Scheduling Policies 
In the final scenario of our main analyses, we examine how different scheduling policies 
impact metrics. We consider the six combinations of in-range and out-of-range policies (A1, A2, 
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B1, B2, C1, and C2). Table 14 indicates metrics for the various policies. We see policies A1 and 
A2 (“A policies”) tend to have different values than B1, B2, C1, and C2 (“B/C policies”). With 
the A policies, patient preferences for modality are met in approximately 50% of appointments, 
because A policies do not consider preference when scheduling. The B/C policies all have 99-
100% preferences met. We also see higher overall utilization and telehealth utilization under the 
A policies versus the B/C policies. We also see a nonsignificant increase in lead time and 
number of out-of-range appointments in the A policies compared to B/C. These small increases 
are due to the slightly higher utilization of providers, especially for F2F appointments. Because 
any appointment can be used, providers are more likely to be unavailable, pushing appointments 
slightly further in time under A policies. 
 
Table 14. Impact of scheduling policies on patient preferences met, utilization, and lead time 
 Scheduling Policy 









100 ±0 99.98 
±0.06 
100 ±0 

































































4.5. Sensitivity Analyses 
We conducted sensitivity analyses to understand which input variables have the greatest 
impact on two key metrics: lead time and provider utilization for telehealth appointments. For 
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each metric a tornado diagram is created, with each bar of the tornado diagram representing one 
input variable. The top bar of the diagram indicates the input variable that has the greatest impact 
on the metric of interest, with subsequent bars included in descending order of impact. Appendix 
A has abbreviation explanations and full variable names. 
Figure 4 shows tornado diagrams for lead time. In all policies, the most influential input 
variables are the number of PCPs, the number of GI physicians, and the lower-bound of the 
range of next appointment scheduling. Regarding number of physicians, we see that having 
fewer physicians, regardless of type, is highly influential on lead time, particularly when moving 




Figure 5 shows the influence of input variables on telehealth utilization across all 
policies. Telehealth utilization under policies A1 and A2 is most influenced by PCP-related input 
variables, including the number and capacity of PCPs. Telehealth utilization under B/C policies 
is most impacted by the probability of patients who live near clinics preferring telehealth 
Figure 4. Impact of input variables on lead time across all policies 
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appointments, which makes sense because these four policies all consider patient preference for 





In this chapter, we demonstrated how simulation can be used to understand how specialty 
care clinics can consider patient preference as they offer new ways of providing care to patients, 
including telehealth. As these modalities are implemented, simulation can be used to help define 
scheduling policies, such as the ones presented in our study of GERD patients. Further, 
simulation helps clinical decision-makers understand the impact of providing telehealth options 
for patients and providers. Simulation also helps these decision-makers adjust their systems to 
accommodate patient needs while maintaining operation objectives, such as achieving a given 
provider utilization or keeping patient lead times under a threshold. 
Figure 5. Impact of input variables on telehealth utilization across all policies 
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 Our simulation models demonstrate that, in our example, accommodating patient 
preference for appointment modality when scheduling specialty care appointments can be done 
with reasonable impact on the system and while incorporating patient preferences for care 
modality. Across the B/C policies, which take patient preference most into account, we see that 
patient preferences are met while achieving short lead times (less than 4-5 weeks in most 
scenarios) and appropriate provider utilization. These metrics are maintained under most 
instances of our sensitivity analyses. In particular, policy C1 indicates a balance between 
meeting patient needs (scheduling the patient for their preferred appointment modality when one 
is available in-range), while also offering scheduling flexibility for provider organizations if the 
patient’s preferred appointment modality is not available in a clinically-indicated timeframe. 
Keeping lead time low will also maintain quality of care because the likelihood of a patient’s 
condition worsening while waiting is smaller. 
 The discrete-event simulation presented here provides a helpful framework for how to 
organize models for other clinical institutions or diagnosis groups. Building on the model 
presented here, future work could include enhancing variable interactions, such as adjusting the 
probability that a patient is a “no-show” depending on whether their scheduled appointment is of 
their preferred modality. Additionally, we can extend this simulation to gain additional insight by 
incorporating financial information to understand impact on costs; imposing maximum lead-time 
policies; considering endogeneity on patient modality preferences due to scheduling policy 
changes; and incorporating additional patient attributes, such as age or socioeconomic status, that 
may impact patient preferences for telehealth. 
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Chapter 4. Evaluating Strategies for Mitigating Patient Backlog for Non-




4.1. Problem Background 
 On January 21, 2020, the Centers for Disease Control and Prevention confirmed the first 
case of the 2019 novel coronavirus, SARS-CoV-2, followed by the United States declaring the 
coronavirus outbreak a public health emergency on January 31. (71,72) On March 13, the United 
States federal government issued a national emergency due to the spread of SARS-CoV-2, while 
days prior the World Health Organization had declared a pandemic due to COVID-19, the 
disease caused by the coronavirus. (73,74) 
 Since that time, the COVID-19 pandemic has led to a remarkable number of 
hospitalizations and other demands on health systems across the country, including the 
cancellation or deferral of non-emergency medical appointments. (75) We can consider non-
emergency appointments to be clinical visits that could be performed at a future date with little 
risk to a patient’s condition worsening due to the delay. The length of time that non-emergency 
procedures can be delayed varies by the patient’s condition and the severity of that condition. 
 During the COVID-19 pandemic, many non-emergency appointments were canceled or 
deferred to reduce the number of people in clinical settings, thus minimizing risk of coronavirus 
 62 
infection. (76) Additionally, during this time, health systems shifted many clinical providers and 
resources to caring for patients with COVID-19 and/or working to prevent coronavirus infection. 
Finally, state- and local-level government restrictions prohibited certain less urgent medical 
procedures from being performed. (77) These factors led to reduced capacity for many 
appointments, especially non-emergency outpatient visits. Outpatient visits are medical 
appointments that are conducted within a single day and do not require the patient to stay 
overnight at a medical facility. 
 
4.1.1. Endoscopy 
In this chapter, we use endoscopy as a demonstrative example of a non-emergency 
outpatient visit that experienced significant numbers of cancellations related to the COVID-19 
pandemic. An endoscopy is a non-surgical gastroenterology (GI) procedure in which a clinician 
examines a patient’s digestive tract using an endoscope, which is a flexible, thin tube with a 
camera at the end. (49) A common type of endoscopy is colonoscopy, in which the colon and 
rectum are examined for cancerous polyps and other indications of disease. Colonoscopy is 
considered the gold standard for screening and diagnosing patients for colorectal cancer and can 
also sometimes be used to treat polyps, bleeding, and other colorectal issues. (78) 
Another common type of endoscopy is esophagogastroduodenoscopy, more commonly 
called upper endoscopy. During an upper endoscopy visit, a clinician examines a patient’s upper 
GI tract, including the esophagus, stomach, and upper small intestine to evaluate issues including 
bleeding, inflammation, ulcers, and tumors. Similar to colonoscopy, upper endoscopy is often 
used for diagnosis, but can also sometimes be used to treat disease. (79) Note that additional 
types of endoscopy exist but we will only include colonoscopy and upper endoscopy in this 
analysis. 
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In either endoscopy visit, the patient is under sedation while being scoped, which usually 
lasts under one hour, with some time prior to scoping to prepare the patient and time after for 
recovery. The total time a patient spends in a clinic for an endoscopy visit is typically under four 
hours. (78,79) 
Patients may seek an endoscopy visit for several reasons, with those reasons related to 
their urgency for the visit. The patient urgency categories discussed here are used in the Veterans 
Health Affairs (VHA) system, as well as in other health systems. The lowest urgency patients are 
those requesting a colonoscopy for screening. These patients have no underlying risk factors for 
colorectal cancer aside from age of at least 50 years. Surveillance patients are seeking 
colonoscopy because they have additional risk factors for disease, often previous malignancies. 
Surveillance patients can be split into two categories, low-risk and high-risk, depending on the 
number and severity of their risk factors, including the size of adenomas previously removed. 
Finally, diagnostic patients are those seeking endoscopy because some previous screening test 
has indicated a high likelihood of disease. In our model, all patients seeking upper endoscopy are 
classified as diagnostic patients, and patients may seek colonoscopy for diagnostic reasons as 
well. The distribution of patient urgency categories in the Ann Arbor VHA is listed in Table 15. 
 




Screening Colonoscopy 23% 
Low-Risk Surveillance Colonoscopy 15% 
High-Risk Surveillance Colonoscopy 15% 
Diagnostic – Colonoscopy 25% 
Diagnostic – Upper Endoscopy 22% 
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4.1.2. FIT: Fecal Immunochemical Tests 
Rather than coming to a clinical facility for a colonoscopy, screening patients can 
alternatively use a fecal immunochemical test (FIT), in which the patient’s stool is examined for 
blood. FIT has been demonstrated to be a clinically effective alternative to colonoscopy for 
screening patients for colorectal cancer, though to maintain effectiveness, patients need to 
participate in FIT more frequently than they would colonoscopy (once per year for FIT compared 
to approximately once every five-seven years for colonoscopy). (50) 
If a patient uses FIT, the clinic provides the supplies needed to collect the sample and the 
patient returns the sample to the clinic, either by traveling to the clinic to return or by returning 
via mail. (80) While FIT still requires resources from the clinical facility and often still requires 
the patient some travel, FIT notably does not require an in-person appointment with a clinician. 
This feature is especially helpful during the COVID-19 pandemic, when colonoscopy 
appointment capacity is reduced. 
If a patient’s FIT result is positive, they are recommended to receive a colonoscopy. In 
this case, their urgency increases and the VHA considers them now to be diagnostic patients 
when they are being scheduled for colonoscopy. Patients who receive negative FIT results do not 
require any further care, but are recommended to continue following screening guidelines, 
including participating in future FIT or screening colonoscopy. 
 
4.1.3. Capacity Reduction and Backlog Mitigation Strategies 
Like many clinical facilities across the country, VHA clinics saw reduced capacity for 
endoscopy during the COVID-19 pandemic, with over 7 million appointments canceled between 
March 15 and May 1, 2020. (76) While there is some evidence to indicate that patients were 
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more likely to delay non-urgent medical care, thus decreasing demand for appointments like 
endoscopy, the patients’ clinical needs related to endoscopy are no different because of COVID-
19. (81) We can therefore assume that approximately the same number of patients should be 
receiving endoscopy or some alternative form of GI care (FIT, etc.), despite the reduction in 
available capacity. Further, we can then assume that while endoscopy appointment capacity was 
reduced, the number of patients waiting for an endoscopy visit was increasing. 
Early in the widespread onset of the COVID-19 pandemic, the capacity for non-
emergency outpatient visits like endoscopy was reduced significantly; in our model, we assume a 
reduction to 5% of standard capacity for the first 10 weeks. (81) As healthcare leaders learned 
more about COVID-19, they determined solutions to keeping patients and providers safe in 
clinical environments. These solutions, as well as mitigation of community-spread COVID-19, 
allowed for more appointment capacity to be gradually readded. Nevertheless, the backlog of 
patients waiting for endoscopy may persist unless the VHA changes how it provides endoscopy 
visits and related care. 
The VHA has identified several strategies to mitigate the potential backlog of patients 
while capacity is reduced. Several strategies triage patients based on urgency of their need for an 
endoscopy and redirect their care. We can also consider operational strategies, including adding 
additional days in which endoscopy is offered to patients. Note that the strategies discussed 
herein do not need to be administered in isolation and our analysis considers their potential 
individual impacts, as well as how they may mitigate backlog when used in combination. 
4.1.3.1. Exchange Strategy 
In the first strategy, Exchange, patients who are requesting an endoscopy for screening 
are redirected to at-home FIT instead of coming into clinic for endoscopy. Because screening 
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patients account for approximately 30% of endoscopy visits, this strategy helps greatly reduce 
the number of patients waiting for an endoscopy visit. 
In the Exchange strategy, all screening patients are recommended to FIT, but some 
percentage of patients “decide” to not use FIT. The patients who “decide” to not use FIT exit the 
system. Of those who do use FIT, some percentage receives a positive result. Those patients who 
receive a positive FIT result, rejoin the queue as diagnostic patients. Those who receive a 
negative result exit the system. 
 
4.1.3.2. Extend Strategy 
In the Extend strategy, low-risk surveillance patients who are seeking endoscopy are 
deferred for two years. This strategy is in relation to updated guidelines from the American 
Society for Gastrointestinal Endoscopy, which indicate that that low-risk surveillance patients 
need to receive endoscopy every 7-10 years to monitor potential disease progression. (82) The 
VHA previously followed a guideline which recommended an interval of 5-10 years between 
endoscopy visits for these patients. (51) At the onset of the COVID-19 pandemic, the low-risk 
surveillance patients seeking endoscopy were being scheduled according to a five-year interval. 
If the Extend strategy is in place, the VHA now shifts these patients to a seven-year interval 
between endoscopy, thus low-risk surveillance patients are deferred for two years before seeking 
an endoscopy. 
 
4.1.3.3. Overtime Strategy 
An operational strategy for mitigating backlog of patients waiting for endoscopy is the 
Overtime strategy. When the VHA uses the Overtime strategy, additional days or portions of 
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days are available for patients to be scheduled for endoscopy. We can assume that endoscopy 
clinics typically operate Monday through Friday, a five-day week. Thus, if the clinic decides to 
add Saturday as an available day for endoscopy visits, the weekly capacity increases by 20%. 
Alternatively, if the clinic is only open for a half-day on Saturday, the weekly capacity would 
increase by 10%.  
In the Overtime strategy, we increase the weekly capacity by 10-40% (one half-day to 
two full days of weekend clinic visits). Note that weekly capacity is increased by a percentage of 
what would be currently offered in a given week under administrative capacity reduction. For 
example, if a clinic typically offers 100 endoscopy visits each week, they may only offer five 
visits each week during the early weeks of the COVID-19 pandemic, a reduction to 5% of their 
original capacity. If the overtime strategy is in place at 20% overtime, the 20% increase in 
capacity is applied to the five visits, so the clinic would offer six endoscopy visits per week. 
4.2. Methods 
We developed a discrete-event simulation model to consider the various strategies for 
assigning patients to endoscopy appointments under reduced capacity. We compare the three 
strategies outlined in the previous section, as well as combinations of those strategies, to each 
other. We also compare these strategies to implementing no strategies (No Triage).  
In the model, patients “arrive” each week to seek endoscopy, with the number of patients 
arriving randomly determined via a Poisson distribution with mean 113 patients. Patients are 
randomly assigned an urgency categorization (screening, low-risk surveillance, etc.) based on the 
distribution indicated in Table 15.  In each week, we first assign patients with the highest 
urgency to endoscopy visits. Diagnostic patients, which include both diagnostic colonoscopy and 
upper endoscopy, are assigned first, then high-risk surveillance, and so on. Within each patient 
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category, those who have been waiting longest are prioritized for assignment. Patients not 
assigned within a given week join a queue. 
Note that we initialize our model with 802 patients already in the system. These patients 
represent those who had appointments at the time of capacity reduction. Within the simulation 
logic these patients must be seen prior to any patients who have “arrived” after the simulation 
starts. These initial patients are not included in any metric calculations. 
Our typical (pre-pandemic) capacity is 110 endoscopy appointments. In our analyses, we 
begin with capacity for endoscopy visits reduced to 5% of typical capacity. After 10 weeks, 
capacity is increased to 50%, and then increased to 100% capacity after 10 more weeks. This 
leads to 14,630 total appointment slots over the course of the simulation, which indicates the 
maximum number of patients we can see without increasing capacity using the Overtime 
strategy. 
Additional baseline inputs are listed in Table 16. The base unit of time in our model is 
weeks. We run the simulation for 150 weeks and replicate 100 times.  With baseline inputs, we 
find the minimum number of replications to be 57 when comparing No Triage to the Exchange 
strategy. (70) Our model typically processes in under five minutes with 100 replications in most 
cases, so we increased to 100 replications for all analyses. Our simulation was coded in C++. 
We report metrics such as number of patients seen, average wait time, and average 
number of patients waiting beyond four weeks for a visit. This final metric is important to VHA 
clinics because patients who wait beyond four weeks are eligible to have their appointment costs 
covered if they seek care from non-VHA providers. In our baseline analyses, we only track these 
patients who wait beyond four weeks, but we also explore scenarios in which those patients leave 
the system with some probability greater than zero. 
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Table 16. Baseline Input Parameters 
Parameter Value Notes 
Weekly New Patient 
Arrivals 
113 Poisson distributed with lambda=113. Source: 
Ann Arbor VHA (Note: See Table 1 for 
distribution of patients by urgency) 
Weekly Endoscopy 
Capacity 
110 Source: Ann Arbor VHA 
Likelihood that Screening 
Patients follow-through with 
FIT 
85% Source: Ann Arbor VHA 
Likelihood of Positive FIT 15% Source: (83) 
Weeks between FIT 
recommendation and result 
4 Source: Ann Arbor VHA 
Patients in system at 
simulation start 
802 Source: Ann Arbor VHA (Note: metric 
calculations do not include these patients) 
Capacity   
Weeks 1-10 5% Source: Ann Arbor VHA 
Weeks 11-20 50% Source: Ann Arbor VHA 
Weeks 21-30 75% Source: Ann Arbor VHA 
Weeks 31-150 100% Source: Ann Arbor VHA 
 
4.3. Results 
4.3.1. Baseline Analyses 
 In our baseline analyses, we compare our three strategies for mitigating patient backlog – 
Exchange, Extend, and Overtime – to each other and to implementing no strategies (No Triage) 
as shown in Table 17. Under No Triage, we see 14,289 patients over 150 weeks, however only 
964 screening patients are seen of approximately 3,900 screening patients who are seeking 
appointments. Further, over 5,000 patients are waiting beyond four weeks and the average wait 
time is 22.8 weeks across all patient categories, with screening patients waiting an average of 
70.3 weeks.  
Table 17. Baseline Analysis Results 
Metric No Triage Exchange Extend Overtime 
Number of Patients Seen 14,289 13,812 14,287 17,198 
Screening 964 0 2,724 3,856 
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Low-Risk Surveillance 2,513 2,513 766 2,519 
High-Risk Surveillance 2,509 2,507 2,512 2,517 
Diagnostic 8,303 8,792 8,285 8,306 
Num. Patients Waiting 
>4 Weeks 
5,445 2,816 3,448 3,732 
Screening 2,960 0 1,854 1,640 
Low-Risk Surveillance 971 1,165 0 787 
High-Risk Surveillance 655 742 685 581 
Diagnostic 869 909 909 724 
Average Wait Time 
(weeks) 
22.8 9.8 14.1 11.3 
Screening 70.3 - 41.3 33.2 
Low-Risk Surveillance 23.1 28.8 0.0 10.1 
High-Risk Surveillance 9.4 10.9 9.4 5.7 
Diagnostic 3.9 4.0 3.8 3.0 
 
When the Exchange strategy is implemented, we see fewer patients for visits, with all 
screening patients being recommended for FIT instead of coming to the clinic for a colonoscopy 
visit. If those patients have a positive FIT, they return to the system as diagnostic patients. With 
the Exchange strategy in place, the number of patients waiting beyond four weeks is 
approximately halved and the average wait time decreases to 9.8 weeks. Note that with this 
strategy in place, the average waiting times for low-risk and high-risk surveillance patients 
increase. This increase is due to the screening patients who have a positive FIT result and return 
for endoscopy as diagnostic patients who are now prioritized ahead of either surveillance group. 
With the Extend strategy, we see approximately the same number of patients overall as 
compared to No Triage, however we see more screening patients and fewer low-risk surveillance 
patients. Both the number of patients waiting beyond four weeks and the average wait time 
decrease to 3,448 and 14.1 weeks, respectively. Notably, the average wait time for screening 
patients still remains extremely high at 41.3 weeks. When the Extend strategy is implemented, 
one should note that several low-risk surveillance patients who have been intentionally deferred 
their endoscopy visit will need an endoscopy visit after the simulation end date. In this case, 
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because low-risk surveillance patients are deferred for two years, there will be approximately 
1,750 low-risk surveillance patients who will need endoscopy visits over the course of the two 
years following simulation end. During the final 46 weeks of the simulation, we will begin 
seeing the low-risk surveillance patients who were deferred during the early weeks of the 
simulation who have now returned for endoscopy following their two-year deferral. 
When incorporating Exchange and/or Extend, we will always see a reduction in the number 
of patients seen because screening and/or low-risk surveillance patients are triaged to an 
alternative to immediate endoscopy. While the VHA seeks to provide the best patient care to all 
eligible patients whenever available, immediately providing an endoscopy visit for all patients is 
not necessarily the ultimate goal, especially when clinically-proven alternatives like those used 
in the Exchange and Extend strategies are available. 
With the Overtime strategy, we see the most patients of any strategy in our baseline 
analysis, with all patients who arrive in the simulation being seen before the simulation ends. If 
the goal of these strategies is to ensure all patients are seen, the Overtime strategy achieves that 
goal. However, because this strategy just increases capacity without triaging lower-urgency 
patients, we see more patients waiting beyond four weeks compared to the Exchange and Extend 
strategies (though still markedly lower than the No Triage strategy) and an average patient wait 
time of 11.3 weeks, which is greater than the Exchange strategy. 
4.3.2. Combining Strategies 
 The Exchange, Extend, and Overtime strategies are not mutually exclusive so we can 
examine how combining strategies impacts our metrics (Table 18). We examine pairs of each 
strategy, as well as all three strategies included at once.  
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Number of Patients 
Seen 
12,072 13,804 15,541 12,074 
Screening 0 0 3,973 0 
Low-Risk 
Surveillance 
767 2,502 766 771 
High-Risk 
Surveillance 
2,509 2,514 2,513 2,512 
Diagnostic 8,796 8,788 8,289 8,791 
Num. Patients Waiting 
>4 Weeks 
1,566 2,110 2,617 1,274 
Screening 0 0 1,203 0 
Low-Risk 
Surveillance 
0 771 0 0 
High-Risk 
Surveillance 
651 539 590 514 
Diagnostic 915 800 824 760 
Average Wait Time 
(weeks) 
5.2 5.2 5.8 3.6 
Screening - - 12.7 - 
Low-Risk 
Surveillance 
0.0 11.3 0.0 0.0 
High-Risk 
Surveillance 
10.9 6.3 5.7 6.3 
Diagnostic 4.0 3.1 3.0 3.1 
 
With Exchange and Extend strategies in place, we see far fewer patients because all 
screening patients are recommended to FIT and all low-risk surveillance patients are deferred for 
two years. Fewer patients wait beyond four weeks and the average wait time is nearly halved 
compared to using the Exchange strategy alone (5.2 weeks with both strategies compared to 9.8 
with Exchange alone). 
With Exchange and Overtime, we see an increase in number of patients seen compared to 
the previous combination of strategies, but more patients are waiting beyond four weeks. The 
Exchange/Overtime combination has the same average wait time as Exchange/Extend (5.2 
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weeks) but the average wait time for diagnostic and high-risk surveillance is shorter with 
Exchange/Overtime, while low-risk surveillance patients are waiting longer. 
Among the combined-strategy scenarios, the most patients are seen (15,541) when both 
Extend and Overtime strategies are used, but we also see the largest number of patients waiting 
beyond four weeks (2,617) and the greatest average patient wait time (5.8 weeks). 
When all strategies are used, a similar number of patients are seen to just Exchange and 
Extend, indicating that we do not need the additional capacity provided by the Overtime strategy 
in order to see all patients with Exchange and Extend in place. That additional capacity does 
allow patients to have visits sooner. This leads to decreases in the number of patients waiting 
beyond four weeks and the average patient wait time. Yet, when all three strategies are used, we 
will have a great deal of unused capacity after the initial backlog of patients receives visits. 
 
4.3.3. Varying Triage Uptake 
Triage strategies may not be able to be fully implemented due to patients and/or providers 
being unwilling to adhere to triage guidelines or inadequate resources (not enough FIT kits, etc.). 
Tables 19 and 20 present results when the Exchange or Extend strategies are not fully 
implemented. The first column of results in each table shows 100% implementation, which will 
have the same results as the respective strategy in Table 17, followed by 75%, 50%, and 25% 
implementation. When a strategy is partially implemented the remaining patients who would 
have used that strategy are processed as though there is no strategy in place. 
Table 19 shows the impact of varying the Exchange strategy. When less than 100% of 
screening patients are triaged to FIT, more patients are seen overall. However, we do not see an 
increase in overall patients seen beyond 75% implementation. This is largely due to some 
screening patients who do participate in FIT returning to the system because of a positive FIT 
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result as diagnostic patients, who are prioritized ahead of screening patients who do not 
participate in FIT. Additionally, as the proportion of screening patients decreases, the number of 
patients waiting beyond 4 weeks increases, as does the average waiting time. 
 








Number of Patients 
Seen 
13,812 14,293 14,290 14,290 
Screening 0 600 723 813 
Num. Patients Waiting 
>4 Weeks 
2,816 3,447 4,230 4,833 
Screening 0 760 1,476 2,252 
Average Wait Time 9.8 13.1 16.6 19.9 
Screening - 66.2 68.9 70.2 
 
Table 20 presents results when the Extend strategy is varied. Unlike the Exchange 
strategy variations, the Extend strategy impacts two patient groups: Screening and Low-Risk 
Surveillance. Because of the prioritization structure of our model, low-risk surveillance patients 
are always prioritized ahead of screening patients. Thus, if fewer low-risk surveillance patients 
are deferred for endoscopy, more of these patients in this group will consume capacity soon after 
their arrival, which will leave fewer visits available to screening patients. As Table 20 
demonstrates, lowering the proportion of patients who follow the Extend strategy has no impact 
on the total number of patients seen, but does lead to large increases in the number of patients 




1 In Tables 19 and 20, all patient categories are included in the simulation as in previous analyses, but these tables 
only report patient categories with metric values that significantly change across scenarios. 
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Table 20. Varying Extend Implementation1 
Metric 100% Extend 75% Extend 50% Extend 25% Extend 
Number of Patients 
Seen 
14,287 14,294 14,292 14,291 
Screening 2,724 2,361 1,878 1,501 
Low-Risk Surveillance 766 1,134 1,597 1,996 
Num. Patients Waiting 
>4 Weeks 
3,448 3,795 4,246 4,708 
Screening 1,854 2,057 2,212 2,436 
Low-Risk Surveillance 0 215 459 726 
Average Wait Time 14.1 16.2 18.5 20.3 
Screening 41.3 48.9 57.5 63.5 
Low-Risk Surveillance 0.0 7.4 12.9 17.2 
 
4.3.4. Varying Overtime 
In our earlier analyses, the Overtime strategy considered an increase in capacity of 20%, 
the equivalent of keeping clinics open one full weekend day. We can also consider 10% overtime 
(one weekend half-day) or 40% overtime (two weekend full days), with results shown in Table 
21. With 10% overtime, fewer patients are seen overall compared to 20%, with more patients 
waiting beyond four weeks and a greater average patient wait time. When overtime is increased 
to 40%, we do not see a significant increase in number of patients seen, but there is a meaningful 
decrease in the number of patients waiting beyond four weeks and average patient wait time. 
With 40% overtime, there will surely be unused capacity throughout much of the simulation 
period, as shown in Figure 6, which indicates number of patients seen by week. Under the 20% 
Overtime strategy, we use all available capacity for nearly all of the simulation period. 
Conversely, under the 40% Overtime strategy, we have available capacity through most of the 




Table 21. Varying Overtime Implementation 
Metric 10% Overtime 20% Overtime 40% Overtime 
Number of Patients Seen 15,748 17,198 17,290 
Screening 2,446 3,856 3,964 
Low-Risk Surveillance 2,505 2,519 2,502 
High-Risk Surveillance 2,499 2,517 2,510 
Diagnostic 8,298 8,306 8,314 
Num. Patients Waiting >4 
Weeks 
4,443 3,732 2,870 
Screening 2,106 1,640 1,152 
Low-Risk Surveillance 868 787 560 
High-Risk Surveillance 617 581 463 
Diagnostic 852 724 695 
Average Wait Time 17.0 11.3 5.7 
Screening 53.5 33.2 13.0 
Low-Risk Surveillance 14.2 10.1 6.3 
High-Risk Surveillance 7.2 5.7 4.3 
Diagnostic 3.4 3.0 2.5 
 
 
Figure 6. Number of Patients Seen by Week Under Two Overtime Strategies 
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4.3.5. Sensitivity Analyses of Assumed Inputs 
While no simulation model can fully capture reality, we can conduct sensitivity analyses 
to ensure we are capturing more potential realistic scenarios. Table 22 presents examples of such 
scenarios. In all scenarios, we assume the Exchange and Extend strategies are both used, with the 
first column of results presenting the same output as was shown in the original combined 
strategy table (Table 18). In the next two columns, we show results that change the average 
number of weekly arrivals, first by increasing by 25%, then by decreasing by 25%. The 
decreased arrival rate is particularly helpful because patients may have been less likely to seek 
non-emergency care during the COVID-19 pandemic. The results in these columns indicate a 
direct relationship between arrival rate and all of our metrics. That is, increasing the arrival rate 
leads to an increase in number of patients seen, number of patients waiting beyond four weeks, 
and average wait time. Decreasing arrival rate leads to decreases in these metrics. 











if Wait >4 wks 
1.0 Prob. 
Patient Leaves 
if Wait >4 wks 
Number of Patients 
Seen 
12,072 14,211 9,090 10,683 10,646 
Screening 0 0 0 0 0 
Low-Risk Surveillance 767 130 577 771 771 
High-Risk 
Surveillance 
2,509 3,126 1,878 2,143 2,168 
Diagnostic 8,796 10,955 6,635 7,769 7,707 
Num. Patients Waiting 
>4 Weeks 
1,566 3,703 992 213 0 
Screening 0 0 0 0 0 
Low-Risk Surveillance 0 844 0 0 0 
High-Risk 
Surveillance 
651 1,391 393 53 0 
Diagnostic 915 1,468 599 160 0 
Average Wait Time 5.2 12.5 3.1 0.2 0.1 
Screening - - - - - 




10.9 32.4 5.0 0.2 0.1 
Diagnostic 4.0 5.9 2.8 0.2 0.1 
 
We can also consider patients leaving the system if they wait beyond four weeks, as 
shown in the final two columns of Table 22. As previously mentioned, VHA patients who have 
waited for an appointment for more than four weeks may seek care from a non-VHA provider, 
with the VHA covering appointment costs. Thus, we consider patients leaving the queue if they 
wait more than four weeks with some probability of 0.5 and 1.0. In each of these scenarios, far 
fewer patients are seen overall because so many patients have left the system and wait time is 
near zero.  
4.4. Conclusions 
COVID-19 has caused significant disruptions to healthcare operations, including reduced 
capacity for non-emergency procedures like endoscopy. The simulation model described in this 
chapter can help clinical decision-makers understand how pandemic-influenced reduced capacity 
for non-emergency procedures could impact patient wait time and other important metrics. 
Further, decision-makers can adjust their reopening plans and triage strategies to help achieve 
meaningful outcomes for patients, while ensuring patients are seen in a clinically beneficial and 
patient-centered timeframe. 
Our model does not aim to find the “best” strategy to mitigate patient backlog for 
endoscopy visits in the VHA. Rather, it provides additional information in the decision-making 
process of VHA leaders in their pursuit of the best possible patient care. If their goal is to have 
the most patients possible receive endoscopy visits within the simulation time period, the 
Overtime strategy will prove most beneficial of the strategies reviewed. However, because this 
strategy alone does not triage lower-urgency patients, the number of patients waiting beyond four 
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weeks is high. To ensure average waiting time remains relatively low, both overall and within 
each patient category, one or both of the Exchange and Extend strategies may be included so 
screening and/or low-risk surveillance patients can be triaged to an alternative form of care. 
VHA leaders should consider that triage strategies may not be universally accepted by 
patients. For example, a low-risk surveillance patient may not want to defer their colonoscopy 
for two years, preferring instead to be seen as soon as possible. Additionally, the VHA may not 
want to shift operational or financial resources to FIT or deferred colonoscopy visits as is 
required in the Exchange and Extend strategies, respectively. For these reasons, the VHA should 
consider potential outcomes under partial uptake of patient triage strategies, as outlined in Tables 
19 and 20. 
This chapter’s model has limitations. First, the prioritization structure of patient visit 
assignments is relatively rigid in its hierarchy of patient risk categories. In reality, a high-risk 
surveillance patient who has been waiting to be seen for 12 weeks may be prioritized over a 
newly-arrived diagnostic patient. However, within the confines of the reduced capacity due to 
COVID-19, the assumption of a strict hierarchical prioritization is more reasonable. 
An additional limitation is that our model is strict in strategy implementation. Analyses 
assume that a strategy carries throughout the entire simulation period, even if patient backlog has 
been relatively well-resolved. Given that the impact of COVID-19 has been somewhat 
unpredictable and such strategies may need to be used longer than expected, this limitation 
seems acceptable. Further, because the two patient triage strategies, Exchange and Extend, are 
both clinically-proven alternatives to endoscopy visits, one can assume that continuing using 
these strategies after backlog has been resolved will not lead to patient harm. 
 80 
Each strategy discussed requires consideration from the VHA in how it is implemented. 
Specifically, the VHA must weigh the trade-offs between the reduction in patient backlog and 
each strategy’s additional outcomes. With the Exchange strategy the VHA needs to ensure it has 
the resources and capacity to handle increased FIT processing, as well as the increase in number 
of diagnostic patients needing colonoscopy visits following a positive FIT result. Under Extend, 
the VHA is delaying a subgroup of patients from receiving colonoscopy visits for two years. This 
reduces current patient backlog but could lead to subsequent increased system-level burden 
and/or patient backlog if the future operational state is unable to handle the deferred patients 
well. The Overtime strategy widely benefits patients by allowing more patients to be seen and 
reducing wait time, but may negatively impact clinicians and other staff due to burnout and/or 
increased exposure to risk of COVID-19 infection. 
The simulation model described in this chapter could be applied to other non-emergency 
outpatient procedures, particularly those that include a range of patient categories who may 
utilize those procedures, including primary care annual physical examinations, dental visits, or 
other cancer screening/diagnostic procedures. Further, this simulation model could be used 
during non-pandemic time periods to examine impact of new policies or triage strategies. 
Finally, while our model inputs were specific to the VHA location in Ann Arbor, 
Michigan, the structure and logic of the model can be applied to other VHA locations across the 
country. We have begun working with the national GI office within the VHA to apply these 
strategies in different settings that may have different relationships between patient arrivals and 
capacity or different rates of reopening capacity. With this cross-clinic comparison, we may 
identify how various strategies or combinations of strategies can impact clinics with different 
types of parameters. 
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Chapter 5. Assessing the Impact of Incorporating Predictive Modeling into Chronic Liver 
Disease Appointment Decision-Making 
 
Chronic liver disease (CLD) is a potentially fatal disease, and it is sometimes difficult to 
detect because of its long asymptomatic phase. A new tool known as analytic morphomics uses 
predictive modeling to diagnose CLD earlier and more accurately. In this chapter, we use 
discrete-event simulation to model how patients referred for CLD could be assigned to 
appointments based on the severity of patients’ disease under various clinical decision models, 
including analytic morphomics. We consider each decision model’s predictive power and 
policies about collecting patient data used for model inputs. This work can help clinics 
assign CLD patients more accurately to an appointment type that best aligns with patient needs. 
5.1. Problem Background 
Predictive modeling broadly describes a mathematical methodology that considers a set 
of inputs and uses historical relationships to estimate outcomes of interest. The relationships in 
these models are computationally driven by statistics. Engineers often design the structure of the 
model, including how the components interact. Predictive modeling has been applied to several 
domains, including healthcare.  
An objective of using predictive modeling is to improve precision in decision-making. 
For example, a predictive model could use data from a hospitalized patient’s medical record to 
determine how likely they are to be readmitted if they are discharged today versus tomorrow. 
(84) Clinical providers can use this information in discussions with patients about discharge 
decisions, which can lead to improved outcomes. 
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However, little work has been done to examine how using these predictive models in 
practice impacts system-level operations and outcomes. If a hospital were to implement the 
readmission prediction model described in the previous paragraph, using this model may lead to 
an increase in the average hospital length of stay in efforts to minimize future readmissions. With 
many patients having longer stays, the hospital may see overcrowding now, which could be 
operationally challenging, as well as potentially harmful to patients. 
This chapter explores system-level outcomes of incorporating predictive modeling in 
decision-making. Specifically, we use discrete-event simulation to examine how a Veterans 
Health Affairs (VHA) hepatology clinic could use predictive modeling outcomes to determine a 
patient appointment type when patients are referred for chronic liver disease (CLD), compared to 
other non-predictive diagnostic models. We consider how using predictive modeling changes 
outcomes based on current state appointment assignments and how the clinic may need to adjust 
operations to accommodate those changes. We also explore how the characteristics of the 
predictive model could impact outcomes by analyzing results when models’ predictive powers 
are altered. 
5.1.1. Predictive Modeling and Medical Decision-Making 
Clinicians and other healthcare leaders have been utilizing computers and other 
technology to support and/or guide their decision-making processes since the 1950s. (85–87) 
Computers are often used in healthcare to improve patient outcomes by improving precision of 
diagnoses or treatment planning or to improve system-level outcomes by increasing operational 
efficiency. In these capacities computers and other technological tools supplement human-level 
decision-making by confirming or questioning a clinician’s medical decision given some clinical 
information. An example of this would include a flag in a patient’s electronic health record 
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alerting a clinician that two prescribed medications may have a harmful interaction.  (88) 
Additionally, technology may be used to expedite the processing of information in the form of 
complex algorithmic calculations. 
Predictive modeling in particular has been commonly used in guiding diagnosis and 
treatment, especially in classification. Classification is a process of putting objects – in this case, 
the objects are often patients – into predefined categories based on the objects’ characteristics. 
For example, a patient’s glucose levels can be used to categorize their diabetes status into three 
buckets: normal (no diabetes), prediabetes, and diabetes. (89) We thus use quantitative patient 
information to classify the patient as one of three categorical diagnoses of this chronic disease.  
As a tool, predictive modeling can be especially helpful in medical decision-making 
because it has the potential to prevent patient harm, improve clinical outcomes, and improve 
value. In many contexts, predictive modeling may reduce the number of diagnostic or screening 
tests needed to accurately diagnose a patient for given condition, which reduces the likelihood of 
a patient incurring harm during that testing. (90) Under some scenarios, predictive modeling may 
alternatively increase the amount of testing performed. Additionally, predictive modeling may 
improve the precision of those results, which can improve treatment planning and lead to better 
patient outcomes. (91) Finally, because fewer diagnostic tests may be needed and care is more 
personalized to a specific patient, a system may reduce unnecessary or wasteful procedures, thus 
decreasing costs and improving the value of care provided. (92)  
Nevertheless, when predictive models are considered in healthcare, the impact is 
generally focused on improving outcomes for a specific patient or patient group by indicating 
that diagnostic accuracy for a given disease is improved by some percentage. As we discuss 
throughout this chapter, more work is needed to understand broader system-level outcomes of 
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implementing predictive modeling into standard care pathways. This chapter will help us explore 
how incorporating predictive modeling may impact system-level operations, as well as how 
changing a model’s predictive power impacts the larger system. This type of exploration can be 
helpful in determining how predictive models could impact access to care. 
 
5.1.2. Chronic Liver Disease in the VHA 
Chronic liver disease (CLD) is a condition in which a patient’s liver functioning has 
progressively deteriorated for at least six months. CLD could be caused by many related 
conditions, including chronic hepatitis infection, excessive use of alcohol, non-alcoholic fatty 
liver disease, and genetics. Individuals with CLD are treated by hepatologists, physicians who 
specialize in diseases of the liver. (93) 
CLD patients at the Ann Arbor Veterans Health Affairs (VHA) hepatology clinic are 
referred for consultation by non-hepatology providers, usually primary care providers (PCPs). 
PCPs commonly refer patients for CLD consultation based on risk factors including Hepatitis C 
infection, liver masses found in imaging, and cirrhosis. (94) Cirrhosis is scarring of the liver 
tissue and it indicates late-stage, more severe CLD. (93) Cirrhosis is diagnosed by a PCP using 
blood tests and imaging tests, like computed tomography (CT) or magnetic resonance imaging 
(MRI). (95) CLD has a long asymptomatic phase, making it difficult to precisely diagnose early 
in disease onset. 
Severity of CLD can be categorized in multiple ways; within this chapter we consider 
three stages: mild, moderate, and severe. Mild CLD indicates liver disease but no cirrhosis 
present. Moderate CLD indicates liver disease with some cirrhosis. Severe CLD indicates liver 
disease with decompensated cirrhosis. A patient with mild or moderate CLD who is left 
untreated is likely to progress to a more severe disease state. In our simulation model, we 
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consider a cohort of patients referred to a hepatology clinic, thus they are likely to have at least 
mild CLD. Thus, we do not consider patients with no CLD. 
In the current state, when a CLD patient is referred to the hepatology clinic of the Ann 
Arbor VHA, a trained non-clinician scheduler will determine if and how the patient receives a 
consultation, based on the patient’s clinical information and perceived CLD severity. Patients 
who seem to have severe CLD are most likely to receive a consultation, which is performed 
during an in-person appointment with the hepatologist.2 Patients perceived to have mild CLD 
may not receive an appointment, and if they do it would more likely be an electronic consult (e-
consult), which is an asynchronous provider-to-provider communication within an electronic 
health record. (96) Patients who are perceived somewhere between mild and severe CLD (within 
a group of “moderate” CLD patients) generally receive some type of appointment, but it could be 
in-person, e-consult, or a virtual and synchronous visit. Note that within this specific clinic, most 
referred CLD patients are nearly always offered some type of appointment so that patients feel 
they are not being neglected and satisfaction is maintained. 
5.1.3. Evaluating Chronic Liver Disease 
Fully understanding a patient’s chronic liver disease severity can be difficult, especially 
in early-stage CLD. While liver biopsy remains the gold standard for diagnosing most 
hepatological diseases, biopsy is invasive and may lead to patient harm. (97) Several models, 
algorithms, and scoring systems have been developed to assist clinicians, schedulers, and others 
in better understanding a patient’s true disease state without biopsy. For our work, we will 
consider three methods for evaluating CLD status: FIB4 index, Child-Turcotte-Pugh (CTP) 
 
 
2 During the COVID-19 pandemic, appointments typically performed in-person may have been conducted virtually. 
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score, and analytic morphomics. The first two methods, FIB4 index and CTP score are more 
commonly used in current practice and yield an objective value to descriptively indicate a 
patient’s current disease state. Analytic morphomics is a newer method that uses machine 
learning methods to more accurately understand a patient’s current disease state, while also 
predicting currently asymptomatic CLD.  
 5.1.3.1. FIB4 Index 
The FIB4 index uses four patient data elements (patient age, platelet count, and two 
different liver enzyme levels, aspartate aminotransferase and alanine aminotransferase) to predict 
fibrosis, an elevated level of scar tissue in the liver. (97) These data are combined in the 
following formula to calculate FIB4 index: 
𝐹𝐼𝐵4 𝐼𝑛𝑑𝑒𝑥 =  
𝑎𝑔𝑒 ∗ (𝑎𝑠𝑝𝑎𝑟𝑎𝑡𝑒 𝑎𝑚𝑖𝑛𝑜𝑡𝑟𝑎𝑛𝑠𝑓𝑒𝑟𝑎𝑠𝑒)
(𝑝𝑙𝑎𝑡𝑒𝑙𝑒𝑡 𝑐𝑜𝑢𝑛𝑡) ∗ √(𝑎𝑙𝑎𝑛𝑖𝑛𝑒 𝑎𝑚𝑖𝑛𝑜𝑡𝑟𝑎𝑛𝑠𝑓𝑒𝑟𝑎𝑠𝑒)
 
The resulting value indicates the predicted level of fibrosis on scale between 0.2 and 10. 
Patients with a FIB4 index less than 1.45 are highly likely to have mild CLD and a FIB4 index 
over 3.25 indicates high likelihood of severe CLD. (97) An advantage of this method is that most 
patients referred to the hepatology clinic for CLD have the necessary data to calculate the FIB4 
index. (98) A disadvantage of the FIB4 index is that a value between 1.45-3.25 does not yield a 
conclusive indication of a patient’s CLD state. 
5.1.3.2. Child-Turcotte-Pugh Score 
 The Child-Turcotte-Pugh Score (CTP Score) helps classify patients’ liver disease and 
cirrhosis progression using five clinical features: bilirubin levels, albumin levels, prothrombin 
time (related to blood clotting speed), ascites (fluid build-up), and hepatic encephalopathy (loss 
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of brain-function due to liver disease). (99) These features are combined in the following table 
that indicates a number of points a patient accrues based on their features: 
Table 23. Calculation of the Child-Turcotte-Pugh Score 
Factor 1 point 2 points 3 points 
Total bilirubin (μmol/L) <34 34-50 >50 
Serum albumin (g/L) >35 28-35 <28 
Prothrombin time international 
normalized ratio 
<1.7 1.71-2.30 >2.30 
Ascites None Mild Moderate-Severe 
Hepatic encephalopathy None Mild to Moderate Severe 
 
 The sum of the points for each feature result in a CTP score. A CTP score of 5-6 
indicates mild to no CLD, a score of 7-9 indicates moderate CLD, and a score over 9 indicates 
severe CLD. (99) Unlike the FIB4 index, the data required for the CTP score is not as commonly 
found within patient records, so providers may need to require additional testing/data collection 
to calculate a CTP score. 
5.1.3.3. Morphomics 
 The FIB4 index and CTP score both use clinical data as inputs to calculate a quantitative 
value to guide clinicians in diagnosing CLD, however neither of these models would be 
classified as a “predictive model.” In contrast, a recently developed tool, morphomics, uses 
predictive modeling in guiding CLD diagnosis. 
 The morphomics model (or, more completely, “analytic morphomics model”) is a 
logistics regression model with elastic net regularization. The primary feature of the morphomics 
model is a computed tomography (CT) scan, but the model also considers several other values 
from a patient’s medical record including patient demographics and laboratory test values. The 
morphomics model can also include the results of other hepatologic algorithms, like the FIB4 
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index, as a feature used in predicting CLD severity. (100) The morphomics model classifies 
patients into non-cirrhosis (mild CLD) or cirrhosis (moderate or severe CLD) categories. 
 A key advantage of using the morphomics model is that it is effective at detecting CLD 
early in disease onset. A disadvantage of the morphomics model is that it requires a patient 
having a CT scan within the past 6 months, as well as many recent test results. While providers 
who would like to use morphomics in better understanding a patient’s true CLD severity can 
refer a patient for a CT scan and other additional testing, these referrals can be costly and 
burdensome for the patient. We explore the trade-offs of this and other considerations in our 
simulation model. 
5.2. Methods 
 We developed a discrete-event simulation model to consider various policies (outlined in 
Section 5.2.1) to consider CLD appointment decision-making using various clinical decision 
models, including the FIB4 index, CTP score, and morphomics. We compare these policies 
under several scenarios, as detailed in Section 5.2.2. 
 Our model includes a pathway as outlined in Figure 1. In each replication a number of 
patients “arrives” to indicate they are being referred to the VHA hepatology clinic. For the 
analyses presented in this chapter, we set this number to be 77,597, which represents the number 
of patients who visited the Ann Arbor VHA Hepatology Clinic from 2008-2014. Each patient 
who arrives has some probability of having the tests and other data required to run each of the 
three clinical decision models. Each patient also has some true disease state which is hidden from 
the perspective of the appointment decision-maker. 
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Figure 7. Chronic Liver Disease Patient Flow 
 
 Depending on the policy being used and the availability of data for a given patient, a 
decision model is used to estimate a patient’s disease state (Decision 1). The results of this 
decision model are the patient’s predicted disease state and a binary indicator of confidence in 
that prediction. Depending on the policy and what data the patient currently has, a patient may be 
“sent” to gather additional tests or other data, which may improve the confidence in the predicted 
disease state (Decision 1a). If a patient is sent for additional data collection, we track the 
additional tests performed and then the patient returns to Decision 1. 
 After decision model results have yielded sufficient confidence according to our policy, a 
decision is made about what type of appointment a patient should be offered (Decision 2). As 
discussed in Section 5.1.2., a patient’s clinically-ideal appointment is based on the patient’s true 
disease state, with severe CLD patients indicating a need for in-person appointments and 
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moderate CLD patients being referred for telehealth appointments. Mild CLD patients are 
recommended less intensive appointments, like e-consult. In our simulation model we also 
consider another low-intensive “appointment” type called population management. Population 
management involves the referring provider, often a primary care practitioner, to monitor a 
patient’s health over time instead of the patient receiving a hepatology appointment. Population 
management is not commonly used in VHA referring clinics currently, but our clinical 
collaborators indicated it could be a reasonable option for mild CLD patients and should be 
included in our simulation model. Because population management is a less-intensive 
appointment, we only recommend a patient for this type of appointment if we have high 
confidence in our prediction of their disease state. For our model, we consider any prediction that 
uses morphomics to infer high confidence. Thus, any patient who is predicted to have mild CLD 
using a decision model that includes morphomics is recommended for population management; 
any patient predicted to have mild CLD using another decision model is referred to an e-consult. 
 Once a patient has been recommended for an appointment, the patient’s true disease state 
is “revealed,” allowing us to calculate metrics using various policies under difference scenarios. 
Metrics include how often true disease state was accurately predicted, number of various 
appointment types provided, and how often patients were sent to gather additional test results or 
other information. We consider metrics across all disease states and also stratified by disease 
state to examine if various policies are more helpful for certain patient subgroups.  
 Input data for our simulation model comes from previously published studies on CLD 
decision models and operational data from the Ann Arbor VHA Hepatology Clinic. An overview 
of the input data is outlined in Table 24. 
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Table 24. Baseline Input Parameters 
Parameter Value 
Number of patients 77,597* 
Proportion of true disease state among patients  
Mild CLD 89.6% 
Moderate CLD 5.8% 
Severe CLD 4.6% 
Probability that patients arrive with tests to run decision model  
FIB4 Index 79% 
CTP Score 35% 
Morphomics 29% 
* Represents CLD patients from 2008-2014 
 
 We use several clinical decision models as discussed in previous paragraphs. The 
predictive accuracy of each of those models is incorporated into our simulation using a disease 
prediction matrix, as exemplified in Figure 8. See Appendix B for all baseline values for each 
decision model. Broadly, these matrices indicate the probability a disease state will be predicted, 
given a patient’s true disease state, for each decision model (FIB4, CTP, and morphomics). We 
also include matrices for using two or three decision models when patients have the data needed 
for more than one decision model and the policy permits combining decision models. We assume 
that when more than one decision model is used to predict a patient’s disease state, the combined 
decision models will be superior to either single model. For example, using both a FIB4 index 
and a CTP score will yield more accurate predictions than using FIB4 index or CTP score alone. 
 
Figure 8. Sample Disease Prediction Matrix 
  Predicted State 












Mild CLD A1% B1% C1% 
Moderate 
CLD 
A2% B2% C2% 
Severe CLD (1-A1-A2)% (1-B1-B2)% (1-C1-C2)% 
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 In addition to prediction matrices for our three clinical decision models (FIB4, CTP, and 
morphomics) and their combinations, we also include a “general prediction matrix” (also in 
Appendix B) which indicates how the disease state for patients referred for CLD may be 
estimated in the absence of clinical decision models. The values in all of our prediction matrices 
are provided by the Ann Arbor VHA Hepatology Clinic, based on a population of referred CLD 
patients.  
5.2.1. Policies 
 Several policies could be used to examine the impact of access when incorporating 
predictive models into CLD appointment decisions. In this chapter, we will focus on six main 
policies: (A) no decision models used, (B) no additional testing, (C) FIB4 testing required, (D) 
CTP testing required, (E) morphomics testing required, and (F) all testing required. Regardless of 
the policy in place, we assume that if a patient has the testing required for a decision model and 
the policy permits that model can be used, we always include it in our disease prediction. 
Under Policy A, we only use the general prediction matrix to determine a patient’s 
predicted disease state, ignoring any tests or data the patient has. Policy A is largely used as a 
reference case for our other policies. 
 Under Policy B (no additional testing), we can only use the information (demographics, 
lab/imaging results, etc.) that a patient has when they are referred to hepatology for CLD. Under 
this policy, a patient’s disease state is predicted using any one (or more) of the decision models 
(FIB4, CTP, or Morphomics) if a patient has the required data to run the decision model(s). If the 
patient does not have the required data to run any decision model, we use the general prediction 
matrix to estimate disease state. 
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 Under Policies C-E, patients who are referred to hepatology for CLD are required to 
obtain one set of tests to satisfy needs for a given decision model, depending on which policy is 
implemented (FIB4 under Policy C, CTP under Policy D, and Morphomics under Policy E). 
Under each of these policies, our simulation tracks the number of patients who are required to 
obtain additional testing. In reality, this required testing would necessitate additional patient 
appointments, adding to patient burden and increased operational needs for the referring clinic. 
However, this additional testing can improve appropriateness of appointment decisions, which 
may improve patient clinical outcomes. 
 Note that under Policies C-E, a patient may arrive with the necessary testing to run one 
clinical decision model but may have to return for additional testing if it is not the decision 
model highlighted in the specific policy. For example, if Policy E is enforced, a patient is 
required to have morphomics testing. If a patient arrives with the necessary testing to run FIB4, 
they are still required to obtain morphomics testing, but when we use the decision models to 
predict the patient’s disease state, we can use both FIB4 and morphomics, yielding a higher 
predictive power than morphomics alone.  
 Under Policy F, patients are required to obtain testing for all three decision models and 
are returned to gather any testing that they do not have when referred. In this policy, the disease 
prediction matrix that incorporates all three decision models will always be used.  
5.2.2. Scenarios 
 In our analysis, we consider three scenarios: (1) baseline, (2) altering morphomics 
predictive power, (3) altering true disease state distribution. Scenarios 2 and 3 act as sensitivity 
analyses to help us understand how changing the assumptions and inputs of our model can 
impact outcomes.  
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 Scenario 1 (baseline) examines the five policies using baseline parameters, as outlined in 
Table 24, as well as the prediction matrices as outlined in Appendix B. Scenario 2 (altering 
morphomics predictive power) examines our five policies, but with lower/higher predictive 
power for our morphomics decision model. In this scenario, we increase/decrease the values in 
prediction matrices that use morphomics to indicate how changing the accuracy of a predictive 
model has larger impacts. Scenario 2 values are conceptual but allow us to better understand the 
broader impacts that may arise from improving or degrading a predictive model’s power. 
Improvements in predictive power could arise through considering previously unutilized features 
in the analytic morphomics model, while lower predictive power may arise from imprecise test 
results used as input data for the model. 
In scenario 3 (altering true disease state distribution), we increase the proportion of 
patients who have moderate and severe CLD from our baseline distribution. This allows us to 
understand the impacts of using predictive modeling in appointment decision-making in a 
population with more moderate/severe CLD (and thus less mild CLD). 
5.3. Results 
5.3.1. Baseline Results 
 Baseline scenario results are presented in Tables 25 and 26. Compared to Policy A, in 
which we ignore any patient data and use a general prediction matrix to determine a patient’s 
disease state, all policies show improvement in percentage of patients’ true disease states 
correctly predicted. Under Policy B, in which we use any available patient data to inform our 
prediction but do not require any additional testing, the overall percentage correctly predicted is 
64.3%, compared 40.3% in Policy A. For Policies C-E, in which one decision model’s set of 
tests is required, this percentage continues to increase, with Policy E having the highest 
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percentage at 87.4%. If testing is required for all decision models (Policy F), we see the highest 
percentage of correctly predicted disease state at 93.5%. 
The baseline results presented thus far are relatively straightforward; as we use models 
with higher predictive power, we improve the percentage of patients’ disease states correctly 
predicted. We use these results as validation of our model logic, as well as a foundation for 
comparing the analyses discussed in subsequent sections of this chapter.  
 
Table 25. Percentage of Correctly Predicted True Disease State under Baseline Conditions 
 Percentage of True Disease State Correctly Predicted 
Policy Mild Moderate Severe Overall 
A. No Testing Used 40.1% 34.4% 50.8% 40.3% 
B. No Additional Testing 66.5% 41.0% 60.8% 64.7% 
C. FIB4 Required 67.5% 40.4% 61.1% 65.7% 
D. CTP Required 87.4% 44.1% 53.5% 83.2% 
E. Morphomics Required 88.5% 69.2% 89.2% 87.4% 
F. All Testing Required 94.9% 75.1% 90.0% 93.5% 
 
 In Table 26, we can see a high-level perspective of how various policies impact system-
level access. For example, under Policies B-D, some patients have disease state predicted using 
decision models that include morphomics and others do not, thus e-consult and population 
management are both used as appointment recommendations for patients predicted to have mild 
CLD. In Policies E and F, all patients use a model that includes morphomics, thus all patients 
who are predicted to be mild CLD are recommended population management. Table 26 also 
indicates the number of patients who would need to return for additional testing under the 
various policies, with Policy F requiring the most additional testing. Note that the number of 
patients requiring additional testing will not change in future scenarios and are only reported 
here, but one can be assume similar values in other scenarios. 
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Table 26. Appointments Needed and Additional Testing Required under Baseline Conditions 
 
Appointments Needed 







Person FIB4 CTP Morph. 
A. No Testing Used 0 30,054 26,894 20,649 0 0 0 
B. No Additional Testing 17,199 30,518 20,353 9,527 0 0 0 
C. FIB4 Required 17,461 31,028 20,426 8,682 16,435 0 0 
D. CTP Required 18,806 44,114 11,950 2,727 0 50,512 0 
E. Morphomics Required 61,948 0 11,575 4,074 0 0 55,902 
F. All Testing Required 66,484 0 7,285 3,828 16,283 50,678 55,628 
 
 
Taking the results of Tables 25 and 26 together, clinical decision-makers can begin to 
consider trade-offs between increased disease predictions from requiring more testing as shown 
in Table 25, and the additional testing required under various policies. For example, moving 
from Policy B (no additional testing) to Policy C (FIB4 required), the percentage of true disease 
state correctly predicted increases by only 1%, but 16,435 patients will require additional testing 
to calculate a FIB4 index. Moving from Policy B to D (CTP required), we see an increase in 
percentage of true disease state correctly predicted of nearly 20%, but over 50,000 patients will 
require additional testing to calculate a CTP score. 
One can also consider the types of referral appointments used under various policies, 
especially for more resource-intensive appointments like in-person and telehealth visits. Under 
Policy A (no testing used), we see nearly 50,000 telehealth and in-person appointments needed. 
Once we begin to use some decision models (in Policy B onward), the number of needed 
telehealth and in-person visits decreases, while percentage of true disease state correctly 
predicted increases. Compared to Policy A, implementing Policy B sees an almost 25% increase 
of correctly predicted true disease state, a decrease of about 15,000 telehealth/in-person 
appointments needed, and no additional testing appointments required for patients. 
 97 
5.3.2. Altering Morphomics’ Predictive Power Results 
 We next examine results when the predictive powers of our morphomics-based models 
are changed, including one scenario in which predictive power is lower and another in which it is 
higher. The matrices used in these scenarios are included in Appendix C. In general, we 
decrease/increase correct classification probabilities in these matrices by 5%. An exception to 
this change is any morphomics-based models that also use CTP score, which have a high 
probability of correct classification of mild CLD; these values are changed by just 1%.  
 Table 27 presents percentage of patients’ correctly predicted true disease state when the 
morphomics’ predictive power is decreased. Compared to our baseline scenario, all policies 
(except our reference policy, A) show lower percentages of correctly predicted true disease state.  
In Table 28, we also see small changes in the appointments needed. In particular, compared to 
our baseline scenario, we see an increased number of telehealth or in-person appointments 
needed, indicating patients are more likely to be predicted as moderate or severe CLD under 
these conditions. 
 
Table 27. Percentage of Correctly Predicted True Disease State under Lower Morphomics 
Predictive Power Conditions 
 Percentage of True Disease State Correctly Predicted 
Policy Mild Moderate Severe Overall 
A. No Testing Used 40.2% 33.7% 51.3% 40.3% 
B. No Additional Testing 65.6% 38.6% 59.2% 63.8% 
C. FIB4 Required 66.4% 39.9% 58.9% 64.5% 
D. CTP Required 86.0% 39.6% 53.5% 81.9% 
E. Morphomics Required 85.4% 60.7% 84.0% 84.0% 
F. All Testing Required 90.2% 65.0% 85.4% 88.5% 
 
 
Table 28. Appointments Needed under Lower Morphomics Predictive Power Conditions 
 Appointments Needed 
Policy Pop. Mgmt. E-Consult Telehealth In-Person 
A. No Testing Used 0 30,073 26,910 20,614 
B. No Additional Testing 17,010 30,299 20,991 9,297 
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C. FIB4 Required 17,124 30,564 21,148 8,761 
D. CTP Required 17,804 44,356 12,631 2,806 
E. Morphomics Required 60,230 0 13,394 3,973 
F. All Testing Required 63,251 0 10,269 4,077 
 
 Alternatively, we can also consider morphomics-based models to have higher predictive 
power. The results of these analyses are shown in Tables 29 and 30. In Table 29, we see higher 
percentages of patients whose disease state is predicted correctly compared to our baseline 
scenario. Of note, under Policy F, in which all patients’ disease state is predicted using a 
prediction model which incorporates morphomics, FIB4, and CTP, we see the 96% of patients’ 
disease states are correctly predicted. In Table 30, we see that the number of telehealth 
appointments has decreased in all policies compared to our baseline scenario. This is largely due 
to our decision models more often correctly predicting mild or severe CLD in patients, thus not 
misclassifying them as moderate CLD.  
Table 29. Percentage of Correctly Predicted True Disease State under Higher Morphomics 
Predictive Power Conditions 
 Percentage of True Disease State Correctly Predicted 
Policy Mild Moderate Severe Overall 
A. No Testing Used 40.2% 34.6% 49.9% 40.3% 
B. No Additional Testing 67.6% 43.4% 60.9% 65.8% 
C. FIB4 Required 67.9% 44.5% 62.3% 66.3% 
D. CTP Required 87.5% 43.2% 56.0% 83.6% 
E. Morphomics Required 92.4% 77.9% 94.2% 91.6% 
F. All Testing Required 97.1% 80.1% 95.1% 96.0% 
 
Table 30. Appointments Needed under Higher Morphomics Predictive Power Conditions 
 Appointments Needed 
Policy Pop. Mgmt. E-Consult Telehealth In-Person 
A. No Testing Used 0 30,134 26,892 20,571 
B. No Additional Testing 17,967 30,546 19,761 9,323 
C. FIB4 Required 18,107 30,669 20,173 8,648 
D. CTP Required 19,111 44,029 11,598 2,859 
E. Morphomics Required 64,544 0 9,020 4,033 
F. All Testing Required 67,741 0 5,793 4,063 
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 From this scenario’s results, we see that increasing or decreasing the predictive power of 
morphomics-based decision models logically results in a corresponding increase or decrease in 
the percentage of true disease state correctly predicted. When considering morphomics-based 
models with decreased predictive power, policies that use these models still show higher 
percentages of correctly predicted true disease state, though as we see in Table 27, this value for 
Policy E is only slightly greater than in Policy D (CTP required). If morphomics-based models 
were adjusted to have increased predictive power, we see the greatest value in predicting mild 
and severe CLD patients’ true disease state correctly (>90%).   
5.3.3. Altering True Disease State Distribution Results 
 In our final scenario, we alter the distribution of patients’ true disease state. As shown in 
Table 24, in our baseline, approximately 89% of patients have mild CLD, 6% have moderate 
CLD and 5% have severe CLD. In this scenario, we adjust this distribution to be 50% mild CLD, 
25% moderate CLD, and 25% severe CLD. This adjustment allows us to examine how our 
policies may impact the appointments needed if the underlying patient population had more 
moderate/severe CLD than the original cohort.  
 In Table 31, we see that within each patient category (mild, moderate, and severe CLD), 
the percentage of correctly predicted true disease state does not change much from the baseline 
scenario. However, because our distribution of patients’ true disease state is different from the 
baseline, the overall percentages are different in this scenario, with all overall percentages of 
correct predictions lower, apart from our reference policy, A. Because our decision models tend 
to predict mild CLD most accurately, this decrease makes sense. When we have fewer mild CLD 
patients and more moderate/severe CLD patients, our overall accuracy will decrease.  
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Table 31. Percentage of Correctly Predicted True Disease State under Altered True Disease 
State Distribution Conditions 
 Percentage of True Disease State Correctly Predicted 
Policy Mild Moderate Severe Overall 
A. No Testing Used 40.5% 33.8% 50.5% 41.3% 
B. No Additional Testing 66.8% 40.9% 60.0% 58.5% 
C. FIB4 Required 66.6% 42.0% 61.8% 59.3% 
D. CTP Required 87.1% 41.5% 56.2% 68.1% 
E. Morphomics Required 88.7% 69.6% 89.0% 84.0% 
F. All Testing Required 95.0% 75.2% 90.1% 88.8% 
 
 Table 32 indicates the appointments needed when our true disease state distribution is 
altered to include fewer mild CLD patients. Under these conditions, we see far fewer patients 
being referred for population management and e-consult appointments, and more patients 
referred for telehealth and in-person appointments. This shift can be attributed to the more 
moderate and severe CLD patients in the cohort appropriately needing telehealth and in-person 
appointments.  
Table 32. Appointments Needed under Altered True Disease State Distribution Conditions 
 Appointments Needed 
Policy Pop. 
Mgmt. E-Consult Telehealth In-Person 
A. No Testing Used 0 25,911 25,750 25,936 
B. No Additional Testing 10,328 23,243 22,722 21,304 
C. FIB4 Required 10,223 22,548 23,084 21,742 
D. CTP Required 11,003 33,056 18,721 14,817 
E. Morphomics Required 36,775 0 19,959 20,863 
F. All Testing Required 38,659 0 18,470 20,468 
 
The results of this scenario indicate the importance of considering the predictive power of 
decision models in the context of the patient population in which they are applied. When our 
overall patient population includes more moderate and severe CLD patients, our overall 
percentage of correctly predicted disease state decreases compared to our baseline scenario. This 
decrease is because the included decision models are generally worst at correctly predicting 
moderate CLD, so if we increase the proportion of these patients, our percentage of correctly 
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predicted disease state correspondingly decreases. One could therefore consider an ideal patient 
population for our decision models would be one in which there are primarily mild and/or severe 
CLD patients.  
5.4. Conclusions 
 As predictive modeling continues to be incorporated into decision-making about clinical 
appointments, healthcare leaders will need to understand how using such techniques may have a 
system-level impact on operations and patient access. The simulation model presented in this 
chapter demonstrates a tool to guide clinical decision-makers as they determine how best to 
incorporate predictive modeling in making decisions for patients. While we focused on chronic 
liver disease in this chapter, the approach presented here could be applied to other diagnoses in 
which patients can be classified within several categories and multiple models existing in which 
patient data can be analyzed.  
 The results of our model show that predictive modeling can be effectively used to 
increase a provider’s understanding of a patient’s true disease state, thus improving the 
appropriateness of the hepatology appointment recommended to that patient. Depending on the 
policy in place, patients may be required to undergo additional testing, which places burden on 
both the patient and the provider system. Operational and clinical decision-makers can use the 
simulation model results to determine a policy that balances this burden with the positive clinical 
impact derived from additional testing. 
 Policy B, which uses only the information a patient has when they arrive in the system, 
shows a 24.4% increase in percentage of correctly predicted true disease state compared to using 
no testing (Policy A) under baseline conditions. This increase in correctly predicted true disease 
state requires no additional testing burden, but may require a shift in the mix of appointment 
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types to which patients are referred. To improve correct prediction of patients’ true disease state 
even further, decision-makers could implement Policy E (morphomics testing required) or Policy 
F (all testing required), however this will result in increased burden from additional testing. 
 Our second scenario presented an analysis when the predictive power of morphomics-
based models was altered. Logically, if predictive power of these models was decreased, our 
overall percentage of correctly predicted true disease states decreased as well, with the opposite 
effect if predictive power of morphomics-based models was increased. These two scenarios can 
help clinicians and operational leaders understand how a predictive model’s power either 
worsening or improving can impact the overall clinic. Additionally, in our final scenario, we 
considered a cohort that included a higher proportion of moderate and severe CLD patients 
compared to baseline. This scenario demonstrated that underlying disease distribution will have 
an impact on the distribution of appointments needed. For example, our baseline cohort included 
a majority (approximately 90%) of patients with mild CLD versus moderate or severe CLD, 
leading to a large number of population management and e-consult appointments needed. This 
distribution also impacts the overall percentage of patients for whom we correctly predict true 
disease state. 
 The analyses presented in this chapter are intended provide a foundation for future work 
and should be considered as validation for the approach discussed to consider how incorporating 
predictive modeling in appointment decision-making can be modeled using simulation. A 
limitation of our simulation is that patients never get additional testing after their disease state 
has been predicted. In reality, if a provider were not confident about a patient’s predicted disease 
state, the provider may send the patient for additional testing, after which a decision model with 
higher predictive power could be used to estimate a patient’s disease state. Further, our 
 103 
simulation model does not consider any patient attributes aside from their true disease state and 
if they have the testing required for our decision models. Of course, patients have many more 
attributes that may impact what kind of appointment they may be recommended and/or if they 
should be sent for additional testing. Such attributes could include how far the patient lives from 
the clinical location, which could impact if they are willing to comply with requests for 
additional testing and/or their likelihood of attending an in-person hepatology appointment. 
Attributes such as distance to care should be incorporated in future iterations of the simulation 
model presented here. Additional features to include in future versions of this model include 
appointment and testing capacity constraints.  
 In our CLD model, patients were recommended to an appointment that is best aligned to 
their perceived clinical needs, based on their disease state; a severe CLD patient can most benefit 
from an in-person appointment, a moderate CLD patient’s needs can be met with a telehealth 
appointment, while mild CLD patients can be effectively cared for with an e-consult or 
population management. However, regardless of true disease state, patients will likely derive 
some benefit from any appointment type. That is, a severe CLD patient can still benefit from a 
telehealth appointment. When considering additional applications of our approach, accuracy of 
disease state prediction may be more critical based on the resulting appointment decision(s). For 
example, in a different diagnosis, it may be critical to identify severely diseased patients to 
ensure they receive a specific appointment recommendation. In such a case, an effective policy 
will need to require that the decision model(s) used to predict a patient’s disease state are highly 
sensitive to severely diseased patients to ensure those patients receive appropriate care. 
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Chapter 6. Conclusions 
 
This dissertation demonstrated four industrial engineering-based approaches for 
designing healthcare systems to improve access to care for veterans. These methods can be 
helpful both in evaluating systems to understand current state performance as well as in 
designing new systems and policies that concentrate on improving access. While we focused 
primarily on two core methodologies, linear programming and simulation, other industrial 
engineering tools may also be helpful to considering this issue, including Markov processes and 
stochastic optimization modeling. 
 In Chapter 2, we presented a linear programming model to improve veteran access to 
screening and care for chronic eye disease.  This model can serve particularly helpful for 
Veterans Health Affairs (VHA) clinicians and administrators as they seek to screen as many 
patients as possible within the VHA system, as opposed to patients receiving no screening or 
being screened at a non-VHA provider. A strength of our model is demonstrating how the VHA 
system can be redesigned to increase number of patients screened with little additional cost. The 
model presented in Chapter 2 outlined these effects in the state of Georgia and we have used the 
structure of this model to guide the VHA as they plan for expanded eye care in the Central 
Alabama region. This model could continue to be applied to new geographic regions and/or 
additional outpatient VHA services like dermatology. Further, future work could include adding 
greater specificity to our two-step mixed-integer program that incorporates follow-up care for 
those who screen positive for chronic eye disease. For example, rather than a singular probability 
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for screening positive for any eye disease, specific probabilities could be included for several 
diagnoses, each with their own prevalence and required number of follow-up appointments. 
 Chapter 3 discussed a simulation model to incorporate patient preference for appointment 
modality in scheduling policies. Using gastroesophageal reflux disease (GERD) as a 
demonstrative example, we showed that scheduling policies can be constructed to accommodate 
these patient preferences. While our example showed that these patient preferences could be 
accommodated, other clinical contexts (different diagnoses, different patient demographics, etc.) 
may require an increase or decrease in the number of providers needed and/or a change in the 
distribution of appointment types offered by each provider. A key finding in our example was the 
importance of considering how interwoven primary care and specialty care can be. In our GERD 
example, half of the potential appointments were conducted by a primary care provider. 
Although GERD care may often be provided by specialty care providers (here, 
gastroenterologists), understanding the appointment types offered by primary care providers and 
how they align with patient preferences is helpful in ensuring an overall efficient system in 
which patients are seen in a timely manner. Future work of this simulation model may include 
adding additional patient demographics to more robustly incorporate patient preferences. One 
could also add optimization into the simulation model to determine the minimal number of 
appointments offered of a given type to meet patient need under constraints related to allowable 
wait time and number of available providers. 
 In Chapter 4 we developed a simulation model that considered strategies for mitigating 
patient backlog for endoscopy during the COVID-19 pandemic. We discussed several strategies, 
including (1) having some patients conduct at-home testing in lieu of a screening colonoscopy, 
(2) deferring patients who are considered low-risk in colon cancer surveillance for two years, and 
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(3) adding weekend clinic hours to increase weekly capacity. The objective of this simulation 
model was not to identify the best strategy, but rather to help decision-makers understand the 
trade-offs of implementing one or more of these strategies. For example, adding weekend clinic 
hours and incorporating no other strategies allows for the greatest patient volume to be seen over 
the course of our given period. However, compared to one of the first two strategies, many 
patients are waiting excessive amounts of time for their appointments. A clinic can likely receive 
the most benefit from incorporating more than one strategy but may not have the resources 
available to do so. This model has been used to examine VHA operations starting in March 2020, 
when the COVID-19 pandemic began widely impacting clinic capacity. Moving forward, we can 
use the model to understand how future decisions from VHA clinics can help reduce persistent 
patient backlog. Additionally, the simulation model can be updated to more comprehensively 
consider patient outcomes, including adding penalties for patients lost to follow-up when they 
are referred for FIT or incorporating degradation of a patient’s clinical state as they are waiting 
in the queue. 
 Our final simulation model was presented in Chapter 5 and demonstrated system-level 
considerations for incorporating predictive modeling into appointment decision-making. In this 
chapter, we review how a new predictive model, analytic morphomics, can be incorporated into 
appointment decisions for chronic liver disease (CLD). Our simulation results indicated that 
clinicians could use morphomics to improve appointment decision-making. However, depending 
on the policy used when incorporating morphomics into this process, burden may be placed on 
the system and on patients to receive the additional testing required for morphomics to be used. 
Clinical and operational leaders must weigh this burden, as well as their capability to offer the 
necessary referral appointment capacity, when determining the appropriate way to bring 
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morphomics into appointment decision-making. The simulation model presented in this chapter 
lays the foundation for a more detailed model of our considered application in chronic liver 
disease. In future versions of this simulation, features can be added to incorporate a patient’s 
likelihood of attending an appointment, as well as their ability to comply with additional testing 
requests. 
 When considering future work in the domain of this dissertation, a logical next step 
would be the incorporation of equity parameters. While the models discussed herein all aim to 
improve veteran access to care, they do not specifically consider health equity. The mixed-
integer program in Chapter 2 included some constraints to mitigate geographical barriers to 
healthcare access, and the simulation models presented in Chapters 3 and 4 aimed to improve 
access via decreased wait time, yet model features could be added to ensure the patients who 
need care the most are able to receive it. Further, one should consider that as we use these 
models to improve veteran access to care overall, we are not doing so by highly prioritizing one 
patient subgroup and neglecting another. 
 The models presented in this dissertation are all presented with parameters to reflect 
operations in the VHA system. The VHA has several operational and financial structures that are 
helpful when using industrial engineering tools like linear programming and simulation, namely 
that patients often stay within the system to receive care, that costs are relatively centralized, and 
that providers are incentivized to coordinate with others in the system and to ensure patients 
receive preventive care. 
 The features of the VHA system allow our industrial engineering models to be easily 
applied, but we could extend these models to non-VHA systems by adjusting constraints and 
making modifications to model logic. For example, the simulation model in Chapter 4 could be 
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adapted to reflect a non-VHA system by including a probability of patients exiting the queue to 
seek out-of-system care if they have been waiting longer than a given number of weeks for an 
endoscopy appointment and/or an additional stream of patient arrivals that represents external 
arrivals.  Such non-VHA systems would require further details on costs, especially for providers 
who are compensated per patient interaction, unlike salaried VHA providers. However, as 
discussed in Chapter 1, access to healthcare is a national public health issue that extends beyond 







Appendix A. Appendix for Chapter 3 
 
This appendix includes supplementary information related to Chapter 3, including the 
transition probability matrix and tornado diagram abbreviation guide. 
We determine a patient’s next appointment/exit based on a transition probability matrix 
given their current appointment. Note: if a patient is currently at an appointment, they may no-
show, which is indicated by the probability in the matrix of their next appointment being the 
same as their current appointment. 
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The tornado diagrams (Figures 4 and 5) use abbreviated names of input variables. 
Abbreviations and variable descriptions are listed here, as well as the minimum and maximum 





Table 33. Tornado Diagram Abbreviations and Variable Descriptions 
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Appendix B: Decision Model Prediction Matrices for Chapter 5 
 
 
Table 34. General Prediction (No Additional Testing) Decision Model Prediction Matrix 
   Predicted State 







 mildCLD 0.4 0.35 0.25 
moderateCLD 0.33 0.33 0.33 
severeCLD 0.2 0.3 0.5 
 
 
Table 35. CTP Alone Decision Model Prediction Matrix 
   Predicted State 







 mildCLD 0.84 0.16 0.00 
moderateCLD 0.69 0.29 0.02 
severeCLD 0.20 0.64 0.16 
 
 
Table 36. FIB4 Alone Decision Model Prediction Matrix 
   Predicted State 







 mildCLD 0.45 0.40 0.15 
moderateCLD 0.17 0.30 0.53 
severeCLD 0.20 0.29 0.51 
 
Table 37. FIB4+CTP Decision Model Prediction Matrix 
   Predicted State 







 mildCLD 0.84 0.16 0 
moderateCLD 0.43 0.3 0.27 





Table 38. Morphomics Alone Decision Model Prediction Matrix 
   Predicted State 









 mildCLD 0.85 0.15 0 
moderateCLD 0.2 0.6 0.2 
severeCLD 0 0.15 0.85 
 
Table 39. Morphomics+CTP Decision Model Prediction Matrix 
   Predicted State 







 mildCLD 0.95 0.05 0 
moderateCLD 0.2 0.65 0.15 
severeCLD 0 0.15 0.85 
 
 
Table 40. Morphomics+FIB4 Alone Decision Model Prediction Matrix 
   Predicted State 







 mildCLD 0.85 0.15 0 
moderateCLD 0.1 0.7 0.2 
severeCLD 0 0.1 0.9 
 
 
Table 41. Morphomics+CTP+FIB4 Decision Model Prediction Matrix 
   Predicted State 







 mildCLD 0.95 0.05 0 
moderateCLD 0.1 0.75 0.15 
severeCLD 0 0.1 0.9 
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Appendix C: Adjusted Morphomics-Based Decision Model Prediction Matrices for 
Chapter 5, Scenario 2 
 
Note: In this scenario, the values in the General Prediction, CTP Alone, FIB4 Alone, and 
FIB4+CTP matrices do not change. 
Morphomics-Based Prediction Matrices with Lower Predictive Power 
Table 42. Morphomics Alone Decision Model Prediction Matrix with Lower Predictive Power 
   Predicted State 









 mildCLD 0.8 0.2 0 
moderateCLD 0.25 0.5 0.25 
severeCLD 0 0.2 0.8 
 
Table 43. Morphomics+CTP Decision Model Prediction Matrix with Lower Predictive Power 
   Predicted State 







 mildCLD 0.9 0.1 0 
moderateCLD 0.25 0.55 0.2 
severeCLD 0 0.2 0.8 
 
Table 44. Morphomics+FIB4 Decision Model Prediction Matrix with Lower Predictive Power 
   Predicted State 







 mildCLD 0.84 0.16 0 
moderateCLD 0.15 0.6 0.25 






Table 45. Morphomics+CTP+FIB4 Decision Model Prediction Matrix with Lower Predictive 
Power 
   Predicted State 







 mildCLD 0.90 0.05 0 
moderateCLD 0.15 0.65 0.2 
severeCLD 0 0.15 0.85 
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Morphomics-Based Prediction Matrices with Higher Predictive Power 
 
Table 46. Morphomics Alone Decision Model Prediction Matrix with Higher Predictive Power 
   Predicted State 









 mildCLD 0.9 0.1 0 
moderateCLD 0.15 0.7 0.15 
severeCLD 0 0.1 0.9 
 
Table 47. Morphomics+CTP Decision Model Prediction Matrix with Higher Predictive Power 
   Predicted State 







 mildCLD 0.97 0.03 0 
moderateCLD 0.15 0.75 0.1 
severeCLD 0 0.1 0.9 
 
 
Table 48. Morphomics+FIB4 Decision Model Prediction Matrix with Higher Predictive Power 
   Predicted State 







 mildCLD 0.9 0.1 0 
moderateCLD 0.05 0.8 0.15 
severeCLD 0 0.05 0.95 
 
 
Table 49. Morphomics+CTP+FIB4 Decision Model Prediction Matrix with Higher Predictive 
Power 
   Predicted State 







 mildCLD 0.97 0.03 0 
moderateCLD 0.05 0.8 0.15 
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